type: Other Grant/Funding Number

title: EuroSIDA Prospective Observational Cohort Study on Clinical and Virological Outcome of European Patients Infected With HIV

acronym: EuroSIDA

summary:
The EuroSIDA study is a prospective observational cohort study of 23,000+ patients followed in 100+ clinics in 35 European countries, Israel and Argentina. The study is the largest pan-European cohort study and few studies of a comparable design are available on a global scale. The EuroSIDA study is an ongoing collaboration and patients have been enrolled into the study through 11 cohorts since 1994.

The main objective of the study remains the same as in 1994: to prospectively study, clinical, therapeutic, demographic, virological and laboratory data from HIV-1 positive persons across Europe in order to determine their long-term virological, immunological and clinical outcomes.

Historically, EuroSIDA has been crucial in reporting key changes in the HIV epidemic, such as the dramatic changes in morbidity and mortality when combination anti-retroviral therapy (cART) was first introduced. As new anti-HCV treatment is introduced to HIV/HCV co-infected patients, it is important for EuroSIDA to remain in the forefront of investigating the treatment benefits and adverse effects.

All study documents, study status, newsletters, scientific publications and presentations are available online and are updated continuously at project website.

In general terms, the objective of the EuroSIDA study is to continue a long-term, prospective collection of clinical, laboratory and therapeutic data as well as plasma on a large cohort of consecutive HIV infected patients from across Europe in order to (1) assess the factors associated with the clinical, immunological and virological course of HIV infection and HIV-related co-infections and co-morbidities, and (2) continue to provide and develop a surveillance system to describe temporal changes and regional differences in the clinical course of HIV and HIV-related co-infections and co-morbidities in Europe.

status: Enrolling by invitation

study_type: Observational

time_perspective: Prospective

ReferenceType: background

ReferenceCitation: Hill A, Grossman H, Cohen C, Nadler J, Peeters M. Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trial. HIV Clin Trials. 2007 Mar-Apr;8(2):68-76.

ReferenceCitation: Carter M. EuroSIDA cohort: 9% coinfected with HIV/HBV. IAPAC Mon. 2005 Apr;11(4):110.

ReferenceType: result

ReferenceCitation: Podlekareva D, Grint D, Karpov I, Rakmanova A, Mansinho K, Chentsova N, Zeltina I, Losso M, Parczewski M, Lundgren JD, Mocroft A, Kirk O; EuroSIDA in EuroCoord. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study. HIV Med. 2015 Oct;16(9):533-43. doi: 10.1111/hiv.12254. Epub 2015 May 18.

name: CHIP, Department of Infectious Diseases Rigshospitalet; University of Copenhagen; Denmark

family: Podlekareva

full_name: D Podlekareva

given: D

family: Grint

full_name: D Grint

name: Belarus State Medical University; Minsk Belarus

family: Karpov

full_name: I Karpov

given: I

name: Medical Academy Botkin Hospital; St Petersburg Russia

family: Rakmanova

full_name: A Rakmanova

given: A

family: Mansinho

full_name: K Mansinho

given: K

family: Chentsova

full_name: N Chentsova

given: N

name: Riga East University Hospital, Latvian Centre of Infectious Diseases; Riga Latvia

family: Zeltina

full_name: I Zeltina

name: HIV Unit, Hospital JM Ramos Mejia; Buenos Aires Argentina

family: Losso

full_name: M Losso

given: M

family: Parczewski

full_name: M Parczewski

family: Lundgren

full_name: JD Lundgren

given: JD

family: Mocroft

full_name: A Mocroft

family: Kirk

full_name: O Kirk

given: O

journal_name: HIV Medicine

repository_institution: Universita Degli Studi Di Milano - Archivio Istituzionale della Ricerca

repositories_institution: Universita Degli Studi Di Milano - Archivio Istituzionale della Ricerca

publisher: Wiley

publisher_dissemination: Wiley

publisher_group: Wiley

publisher_normalized: Wiley

title: Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

ReferenceCitation: Shepherd L, Borges AH, Ravn L, Harvey R, Jean-Paul V, Bower M, Grulich A, Silverberg M, De Wit S, Kirk O, Lundgren J, Mocroft A; EuroSIDA in Eurocoord. Predictive value of prostate-specific antigen for prostate cancer: a nested case-control study in EuroSIDA. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19510. doi: 10.7448/IAS.17.4.19510. eCollection 2014.

family: Shepherd

full_name: Leah Shepherd

given: Leah

family: Borges

full_name: Álvaro Humberto Borges

given: Álvaro Humberto

family: Ravn

full_name: Lene Ravn

given: Lene

journal_name: Journal of the International AIDS Society

title: Predictive value of prostate-specific antigen for prostate cancer: a nested case-control study in EuroSIDA

ReferenceCitation: Laut KG, Mocroft A, Lazarus J, Reiss P, Rockstroh J, Karpov I, Rakhmanova A, Knysz B, Moreno S, Gargalianos P, Lundgren J, Kirk O; Eurosida in Eurocoord. Regional differences in self-reported HIV care and management in the EuroSIDA study. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19504. doi: 10.7448/IAS.17.4.19504. eCollection 2014.

title: Regional differences in self-reported HIV care and management in the EuroSIDA study

ReferenceCitation: Peters L, Mocroft A, Lundgren J, Grint D, Kirk O, Rockstroh J. HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective. BMC Infect Dis. 2014;14 Suppl 6:S13. doi: 10.1186/1471-2334-14-S6-S13. Epub 2014 Sep 19. Review.

title: HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective

ReferenceCitation: Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren JD, Rockstroh JK, Kirk O, Mocroft A; EuroSIDA in EuroCoord. Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV Med. 2013 Nov;14(10):614-23. doi: 10.1111/hiv.12068. Epub 2013 Jul 19.

name: University of Copenhagen  Copenhagen Denmark

name: University Hospital Basel  Basel Switzerland

repository_institution: Ghent University - Ghent University Academic Bibliography

repository_institution: Landspítali University Hospital - Hirsla

repository_institution: University College London - UCL Discovery

repositories_institution: Ghent University - Ghent University Academic Bibliography

repositories_institution: Landspítali University Hospital - Hirsla

repositories_institution: University College London - UCL Discovery

title: Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA

ReferenceCitation: Podlekareva DN, Reekie J, Mocroft A, Losso M, Rakhmanova AG, Bakowska E, Karpov IA, Lazarus JV, Gatell J, Lundgren JD, Kirk O; EuroSIDA study in EuroCoord. Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study. BMC Infect Dis. 2012 Sep 25;12:229. doi: 10.1186/1471-2334-12-229.

repository_normalized: HELDA - Digital Repository of the University of Helsinki

repositories: HELDA - Digital Repository of the University of Helsinki

repositories_institution:
PubMed Central - Europe PMC
University of Helsinki - Helda

title: Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study

ReferenceCitation: Reekie J, Kowalska JD, Karpov I, Rockstroh J, Karlsson A, Rakhmanova A, Horban A, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord. Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study. PLoS One. 2012;7(7):e41673. doi: 10.1371/journal.pone.0041673. Epub 2012 Jul 23.

repository_institution: Universitat de Barcelona - Dipòsit Digital de la Universitat de Barcelona

repository_institution: DANS - Data Archiving and Networked Services - NARCIS - National Academic Research and Collaborations Information System

repository_institution: University of Sussex - Sussex Research Online

repositories_institution: DANS - Data Archiving and Networked Services - NARCIS - National Academic Research and Collaborations Information System

repositories_institution: Universitat de Barcelona - Dipòsit Digital de la Universitat de Barcelona

repositories_institution: University of Copenhagen - Research at the University of Copenhagen

repositories_institution: University of Sussex - Sussex Research Online

title: Regional Differences in AIDS and Non-AIDS Related Mortality in HIV-Positive Individuals across Europe and Argentina: The EuroSIDA Study

ReferenceCitation: Fox ZV, Cozzi-Lepri A, D'Arminio Monforte A, Karlsson A, Phillips AN, Kronborg G, Kjaer J, Clotet B, Lundgren JD; EuroSIDA. Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA. Antivir Ther. 2011;16(5):781-5. doi: 10.3851/IMP1801.

title: Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA

ReferenceCitation: Viard JP, Souberbielle JC, Kirk O, Reekie J, Knysz B, Losso M, Gatell J, Pedersen C, Bogner JR, Lundgren JD, Mocroft A; EuroSIDA Study Group. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS. 2011 Jun 19;25(10):1305-15. doi: 10.1097/QAD.0b013e328347f6f7.

publisher: Ovid Technologies (Wolters Kluwer Health)

title: Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study

ReferenceCitation: Kowalska JD, Mocroft A, Ledergerber B, Florence E, Ristola M, Begovac J, Sambatakou H, Pedersen C, Lundgren JD, Kirk O; Eurosida Study Group. A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study. HIV Clin Trials. 2011 Mar-Apr;12(2):109-17. doi: 10.1310/hct1202-109.

title: A Standardized Algorithm for Determining the Underlying Cause of Death in HIV Infection as AIDS or non-AIDS Related: Results from the EuroSIDA Study

ReferenceCitation: Reekie J, Reiss P, Ledergerber B, Sedlacek D, Parczewski M, Gatell J, Katlama C, Fätkenheuer G, Lundgren JD, Mocroft A; EuroSIDA study group. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. HIV Med. 2011 May;12(5):259-68. doi: 10.1111/j.1468-1293.2010.00877.x. Epub 2010 Aug 31.

title: A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study

ReferenceCitation: van Luin M, Bannister WP, Mocroft A, Reiss P, Di Perri G, Peytavin G, Molto J, Karlson A, Castagna A, Beniowski M, Lundgren JD, Burger DM; EuroSIDA Study Group. Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study. Antivir Ther. 2009;14(1):75-83.

ReferenceCitation: Podlekareva D, Bannister W, Mocroft A, Abrosimova L, Karpov I, Lundgren JD, Kirk O; EuroSIDA Study Group. The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe--a review of published results. Cent Eur J Public Health. 2008 Sep;16(3):99-105. Review.

ReferenceCitation: Bannister WP, Friis-Møller N, Mocroft A, Viard JP, van Lunzen J, Kirk O, Gargalianos P, Bánhegyi D, Chiesi A, Lundgren JD; EuroSIDA Study Group. Incidence of abacavir hypersensitivity reactions in euroSIDA. Antivir Ther. 2008;13(5):687-96.

ReferenceCitation: Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer J, Reiss P, von Wyl V, Lazzarin A, Katlama C, Phillips AN, Ruiz L, Lundgren JD; EuroSIDA study group. Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):324-33. doi: 10.1097/QAI.0b013e31817ae5c0.

journal_name: JAIDS Journal of Acquired Immune Deficiency Syndromes

title: Transmitted Drug Resistant HIV-1 and Association With Virologic and CD4 Cell Count Response to Combination Antiretroviral Therapy in the EuroSIDA Study

ReferenceCitation: Bannister WP, Ruiz L, Cozzi-Lepri A, Mocroft A, Kirk O, Staszewski S, Loveday C, Karlsson A, Monforte Ad, Clotet B, Lundgren JD; EuroSIDA study group. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS. 2008 Jan 30;22(3):367-76. doi: 10.1097/QAD.0b013e3282f3cc35.

title: Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA

ReferenceCitation: Fessel J, Hurley LB. Incidence of pancreatitis in HIV-infected patients: comment on findings in EuroSIDA cohort. AIDS. 2008 Jan 2;22(1):145-7. Review.

ReferenceCitation: Smith CJ, Olsen CH, Mocroft A, Viard JP, Staszewski S, Panos G, Staub T, Blaxhult A, Vetter N, Lundgren JD. The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. AIDS. 2008 Jan 2;22(1):47-56.

ReferenceCitation: Mocroft A, Ledergerber B, Zilmer K, Kirk O, Hirschel B, Viard JP, Reiss P, Francioli P, Lazzarin A, Machala L, Phillips AN, Lundgren JD; EuroSIDA study group and the Swiss HIV Cohort Study. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. AIDS. 2007 Sep 12;21(14):1867-75.

ReferenceCitation: Podlekareva D, Mocroft A, Dragsted UB, Ledergerber B, Beniowski M, Lazzarin A, Weber J, Clumeck N, Vetter N, Phillips A, Lundgren JD; EuroSIDA study group. Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study. J Infect Dis. 2006 Sep 1;194(5):633-41. Epub 2006 Jul 24.

ReferenceCitation: Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD; EuroSIDA Group. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005 Mar 24;19(6):593-601.

ReferenceCitation: Mocroft A, Monforte Ad, Kirk O, Johnson MA, Friis-Moller N, Banhegyi D, Blaxhult A, Mulcahy F, Gatell JM, Lundgren JD; EuroSIDA study group. Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. HIV Med. 2004 Nov;5(6):437-47.

ReferenceCitation: Cabrera C, Cozzi-Lepri A, Phillips AN, Loveday C, Kirk O, Ait-Khaled M, Reiss P, Kjaer J, Ledergerber B, Lundgren JD, Clotet B, Ruiz L; EuroSIDA Study Group. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study. Antivir Ther. 2004 Oct;9(5):787-800.

ReferenceCitation: Mocroft A, Ledergerber B, Viard JP, Staszewski S, Murphy M, Chiesi A, Horban A, Hansen AB, Phillips AN, Lundgren JD; EuroSIDA Study Group. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J Infect Dis. 2004 Dec 1;190(11):1947-56. Epub 2004 Oct 28.

ReferenceCitation: Kirk O, Mocroft A, Lundgren JD; EuroSIDA-studiet. [Decline in AIDS and death rates in the EuroSIDA study. An observational study]. Ugeskr Laeger. 2004 Jun 21;166(26-31):2572-6. Danish.

ReferenceCitation: Yust I, Fox Z, Burke M, Johnson A, Turner D, Mocroft A, Katlama C, Ledergerber B, Reiss P, Kirk O; EuroSIDA. Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001. Eur J Clin Microbiol Infect Dis. 2004 Jul;23(7):550-9. Epub 2004 Jun 30.

ReferenceCitation: Mocroft A, Kirk O, Clumeck N, Gargalianos-Kakolyris P, Trocha H, Chentsova N, Antunes F, Stellbrink HJ, Phillips AN, Lundgren JD. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. Cancer. 2004 Jun 15;100(12):2644-54.

ReferenceCitation: Dragsted UB, Mocroft A, Vella S, Viard JP, Hansen AB, Panos G, Mercey D, Machala L, Horban A, Lundgren JD; EuroSIDA study group. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. J Infect Dis. 2004 Jul 1;190(1):148-55. Epub 2004 Jun 9.

ReferenceCitation: d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, Justesen US, Vella S, Kirk O, Lundgren J; EuroSIDA Study Group. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol. 2004 Mar;55(3):320-8.

ReferenceCitation: Blasko M. [EuroSIDA Study: downward trend of AIDS cases and AIDS mortality]. Dtsch Med Wochenschr. 2003 Sep 5;128(36):1814. German.

ReferenceCitation: Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A, Panos G, Katlama C, Vella S, Phillips A; EuroSIDA Study Group. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med. 2003 Jul;4(3):255-62.

ReferenceCitation: Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD; EuroSIDA study group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003 Jul 5;362(9377):22-9.

ReferenceCitation: Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, Francioli P, D'Arminio Monforte A, Fox Z, Lundgren JD; EuroSIDA study group. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS. 2002 Aug 16;16(12):1663-71.

ReferenceCitation: Mocroft A, Phillips AN, Friis-Møller N, Colebunders R, Johnson AM, Hirschel B, Saint-Marc T, Staub T, Clotet B, Lundgren JD; EuroSIDA study group. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antivir Ther. 2002 Mar;7(1):21-30.

ReferenceCitation: Lundgren JD, Mocroft A, Gatell JM, Ledergerber B, D'Arminio Monforte A, Hermans P, Goebel FD, Blaxhult A, Kirk O, Phillips AN; EuroSIDA Study Group. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis. 2002 Jan 15;185(2):178-87. Epub 2002 Jan 3. Erratum in: J Infect Dis 2002 Jul 1;186(1):145.

ReferenceCitation: Blaxhult A, Mocroft A, Phillips A, van Lunzen J, Bentwich Z, Stergiou G, Colebunders R, Benfield TL, Mulcahy F, Lundgren JD. Does European or non-European origin influence health care and prognosis for HIV patients in Europe? The EuroSIDA Study Group. HIV Med. 1999 Oct;1(1):2-9.

ReferenceCitation: Viard JP, Mocroft A, Chiesi A, Kirk O, Røge B, Panos G, Vetter N, Bruun JN, Johnson M, Lundgren JD; EuroSIDA Study Group. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis. 2001 Apr 15;183(8):1290-4. Epub 2001 Mar 26.

ReferenceCitation: Mocroft A, Phillips AN, Miller V, Gatell J, van Lunzen J, Parkin JM, Weber R, Roge B, Lazzarin A, Lundgren JD; EuroSIDA study group. The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. AIDS. 2001 Jan 26;15(2):201-9.

ReferenceCitation: Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, Chiesi A, Phillips AN, Kirk O, Lundgren JD. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet. 2000 Jul 22;356(9226):291-6.

ReferenceCitation: Kirk O, Gatell JM, Mocroft A, Pedersen C, Proenca R, Brettle RP, Barton SE, Sudre P, Phillips AN. Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD. Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):865-72. Erratum in: Am J Respir Crit Care Med. 2003 Jun 15;167(12):1719.

ReferenceCitation: Mocroft A, Miller V, Chiesi A, Blaxhult A, Katlama C, Clotet B, Barton S, Lundgren JD. Virological failure among patients on HAART from across Europe: results from the EuroSIDA study. Antivir Ther. 2000 Jun;5(2):107-12.

ReferenceCitation: Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, Katzenstein TL, Antunes F, Lundgren JD, Clotet B. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med. 2000 Apr 24;160(8):1123-32.

ReferenceCitation: Mocroft A, Madge S, Johnson AM, Lazzarin A, Clumeck N, Goebel FD, Viard JP, Gatell J, Blaxhult A, Lundgren JD. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):369-78.

ReferenceCitation: Chiesi A, Mocroft A, Dally LG, Miller V, Katlama C, Ledergerber B, Pedersen C, Phillips AN, Arcieri R, Lundgren JD. Regional survival differences across Europe in HIV-positive people: the EuroSIDA study. AIDS. 1999 Nov 12;13(16):2281-8.

ReferenceCitation: Phillips AN, Grabar S, Tassie JM, Costagliola D, Lundgren JD, Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS. 1999 Oct 22;13(15):2075-82.

ReferenceCitation: Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, Pradier C, dArminio Monforte A, Ledergerber B, Lundgren JD. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS. 1999 May 28;13(8):943-50.

ReferenceCitation: Weverling GJ, Mocroft A, Ledergerber B, Kirk O, Gonzáles-Lahoz J, d'Arminio Monforte A, Proenca R, Phillips AN, Lundgren JD, Reiss P. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet. 1999 Apr 17;353(9161):1293-8.

ReferenceCitation: Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos AI, Katzenstein T, van Lunzen J, Antunes F, Phillips AN, Lundgren JD. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med. 1999 Apr 6;130(7):570-7.

ReferenceCitation: Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, d'Arminio Monforte A, Yust I, Bruun JN, Phillips AN, Lundgren JD. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998 Nov 28;352(9142):1725-30.

ReferenceCitation: Kirk O, Mocroft A, Katzenstein TL, Lazzarin A, Antunes F, Francioli P, Brettle RP, Parkin JM, Gonzales-Lahoz J, Lundgren JD. Changes in use of antiretroviral therapy in regions of Europe over time. EuroSIDA Study Group. AIDS. 1998 Oct 22;12(15):2031-9.

ReferenceCitation: Phillips AN, Katlama C, Barton S, Vella S, Blaxhult A, Clotet B, Goebel FD, Hirschel B, Pedersen C, Lundgren JD. Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Mar 1;17(3):239-44.

ReferenceCitation: Lundgren JD, Phillips AN, Vella S, Katlama C, Ledergerber B, Johnson AM, Reiss P, Gatell J, Clumeck N, Dietrich M, Benfield TL, Nielsen JO, Pedersen C. Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Nov 1;16(3):153-60.

ReferenceCitation: Vingerhoets J, Calvez V, Flandre P, Marcelin AG, Ceccherini-Silberstein F, Perno CF, Mercedes Santoro M, Bateson R, Nelson M, Cozzi-Lepri A, Grarup J, Lundgren J, Incardona F, Kaiser R, Sonnerborg A, Clotet B, Paredes R, Günthard HF, Ledergerber B, Hoogstoel A, Nijs S, Tambuyzer L, Lavreys L, Opsomer M; Etravirine Cohort Study Group. Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. HIV Med. 2015 May;16(5):297-306. doi: 10.1111/hiv.12218. Epub 2015 Jan 14.

name: Janssen Infectious Diseases BVBA; Beerse Belgium

name: ANRS/INSERM; UPMC University of Paris 06; UMR_S 1136; The Pierre Louis Institute of Epidemiology and Public Health; F-75013; University of Sorbonne; Paris France

name: St Stephen's Centre; Chelsea & Westminster Hospital; London UK

name: Informa s.r.l.; EuResist Network GEIE; Rome Italy

name: Institute of Virology; EUResist Network GEIE; University of Cologne; Cologne Germany

name: Karolinska Institute; EUResist Network GEIE; Stockholm Sweden

name: Fight Against AIDS Foundation; Barcelona Spain

name: Swiss HIV Cohort Study; Division of Infectious Diseases and Hospital Epidemiology; University Hospital Zürich; University of Zürich; Zürich Switzerland

repository_institution: Tor Vergata University - Cineca Institutional Research Information System

repositories_institution: Tor Vergata University - Cineca Institutional Research Information System

title: Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data

ReferenceCitation: Marzolini C, Sabin C, Raffi F, Siccardi M, Mussini C, Launay O, Burger D, Roca B, Fehr J, Bonora S, Mocroft A, Obel N, Dauchy FA, Zangerle R, Gogos C, Gianotti N, Ammassari A, Torti C, Ghosn J, Chêne G, Grarup J, Battegay M; Efavirenz, Obesity Project Team on behalf of Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. AIDS. 2015 Jan 14;29(2):193-200. doi: 10.1097/QAD.0000000000000530.

repository_institution: University of Zurich - Zurich Open Repository and Archive

repositories_institution: University of Zurich - Zurich Open Repository and Archive

title: Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults

ReferenceCitation: Antiretroviral Therapy Cohort Collaboration (ART-CC), Vandenhende MA, Ingle S, May M, Chene G, Zangerle R, Van Sighem A, Gill MJ, Schwarze-Zander C, Hernandez-Novoa B, Obel N, Kirk O, Abgrall S, Guest J, Samji H, D'Arminio Monforte A, Llibre JM, Smith C, Cavassini M, Burkholder GA, Shepherd B, Crane HM, Sterne J, Morlat P. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. AIDS. 2015 Jan 28;29(3):373-83. doi: 10.1097/QAD.0000000000000544. Erratum in: AIDS. 2015 Sep 10;29(14):1907.

title: Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients

ReferenceCitation: Boesecke C, Grint D, Soriano V, Lundgren JD, d'Arminio Monforte A, Mitsura VM, Chentsova N, Hadziosmanovic V, Kirk O, Mocroft A, Peters L, Rockstroh JK; EuroSIDA in EuroCoord. Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected? Liver Int. 2015 Nov;35(11):2384-91. doi: 10.1111/liv.12848. Epub 2015 Apr 29.

name: Department of Internal Medicine I; Bonn University Hospital; Bonn Germany

name: Department of Infectious Diseases and Rheumatology; CHIP; Rigshospitalet; Copenhagen Denmark

name: Istituto Di Clinica Malattie Infettive e Tropicale; Milan Italy

name: Gomel State Medical University; Gomel Belarus

name: Klinicki Centar Univerziteta Sarajevo; Sarajevo Bosnia-Herzegovina

title: Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?

ReferenceCitation: Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study. J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-77. doi: 10.1097/QAI.0000000000000523.

title: Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor–Based Combination Antiretroviral Therapy

ReferenceCitation: Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.

name: D:A:D study group, the Royal Free Hospital Clinic Cohort, and the INSIGHT, SMART, and ESPRIT study groups

repository_normalized: University of Melbourne - Minerva Access

repository_institution: The University of Queensland - Queensland's institutional digital repository

repository_institution: Murdoch University - Murdoch Research Repository

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Archive ouverte HAL

repository_institution: University of Ferrara - Institutional Research Information System University of Ferrara

repository_institution: Università Cattolica del Sacro Cuore - PubliCatt

repositories: University of Melbourne - Minerva Access

repositories_institution: Le Centre pour la Communication Scientifique Directe - HAL - Archive ouverte HAL

repositories_institution: Murdoch University - Murdoch Research Repository

repositories_institution: The University of Queensland - Queensland's institutional digital repository

repositories_institution: University of Ferrara - Institutional Research Information System University of Ferrara

repositories_institution: Università Cattolica del Sacro Cuore - PubliCatt

title: Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

ReferenceCitation: Friis-Møller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, De Wit S, Monforte AD, Kirk O, Fontas E, Sabin C, Phillips A, Lundgren J, Law M; D:A:D study group. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol. 2016 Jan;23(2):214-23. doi: 10.1177/2047487315579291. Epub 2015 Apr 16.

name: Odense University Hospital, Department of Infectious Diseases, Denmark

name: Copenhagen HIV Programme, Department of Infectious Diseases and Rheumatology, University of Copenhagen, Denmark

name: Research Department of Infection and Population Health, UCL, London, UK

name: Division of Infectious Diseases, University Hospital Zurich, University of Zurich, Switzerland

name: Academic Medical Centre, University of Amsterdam, and Stichting HIV Monitoring, The Netherlands

name: Department of Infectious Diseases, Centre Hospitalier Universitaire St Pierre Hospital, Brussels, Belgium

name: Department of Infectious Diseases, Hospital San Paolo, University of Milan, Italy

name: Department de Santé Publique, Centre Hospitalier Universitaire de Nice, France

name: 0The Kirby Institute, University of New South Wales, Sydney, Australia

journal_name: European Journal of Preventive Cardiology

title: An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study

ReferenceCitation: Mansfeld M, Skrahina A, Shepherd L, Schultze A, Panteleev AM, Miller RF, Miro JM, Zeltina I, Tetradov S, Furrer H, Kirk O, Grzeszczuk A, Bolokadze N, Matteelli A, Post FA, Lundgren JD, Mocroft A, Efsen A, Podlekareva DN; TB:HIV study group in EuroCoord. Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe. HIV Med. 2015 Oct;16(9):544-52. doi: 10.1111/hiv.12256. Epub 2015 May 11.

name: CHIP (Centre for Health and Infectious Disease Research); Department of Infectious Diseases, Section 2100, Rigshospitalet - University of Copenhagen; Copenhagen Denmark

name: Research Institute of Pulmonology and Pulmonary Tuberculosis; Minsk Belarus

name: Department of Infection and Population Health; University College London Medical School; London UK

name: St Petersburg AIDS Centre; St Petersburg Russia

name: Centre for Sexual Health & HIV Research, Mortimer Market Centre; University College London; London UK

name: Infectious Diseases Service, Hospital Clinic; University of Barcelona; Barcelona Spain

name: Infectology Centre of Latvia; Riga Latvia

name: ‘Dr Victor Babes’ Hospital of Tropical and Infectious Diseases; Bucharest Romania

name: ‘Carol Davila’ University of Medicine and Pharmacy; Bucharest Romania

name: Department of Infectious Diseases; Bern University Hospital and University of Bern; Bern Switzerland

name: Department of Infectious Diseases and Hepatology; Medical University of Bialystok; Bialystok Poland

name: Infectious Diseases; AIDS and Clinical Immunology Research Center; Tbilisi Georgia

name: Institute of Infectious and Tropical Diseases; University of Brescia; Brescia Italy

name: King's College Hospital NHS Foundation Trust; London UK

title: Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe

ReferenceCitation: Schultze A, Phillips AN, Paredes R, Battegay M, Rockstroh JK, Machala L, Tomazic J, Girard PM, Januskevica I, Gronborg-Laut K, Lundgren JD, Cozzi-Lepri A; EuroSIDA in EuroCOORD. HIV resistance testing and detected drug resistance in Europe. AIDS. 2015 Jul 17;29(11):1379-89. doi: 10.1097/QAD.0000000000000708.

title: HIV resistance testing and detected drug resistance in Europe

ReferenceCitation: Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, Smith CJ, d'Arminio Monforte A, Phillips A, Weber R, Lundgren J, Law MG; D:A:D Study Group. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Med. 2016 Apr;17(4):255-68. doi: 10.1111/hiv.12294. Epub 2015 Jul 28.

name: Kirby Institute; UNSW Australia; Sydney NSW Australia

name: Research Department of Infection & Population Health; University College London; London UK

name: Division of Infectious Diseases and Department of Global Health; University of Amsterdam; Amsterdam The Netherlands

name: University of Copenhagen; Copenhagen Denmark

name: Infectious Diseases Department; Saint-Pierre University Hospital; Brussels Belgium

name: University of Milan Clinic of Infectious Diseases; Milan Italy

name: University Hospital in Zurich; Zurich Switzerland

name: Rigshospitalet & University of Copenhagen; Copenhagen Denmark

title: Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study

ReferenceCitation: Grint D, Peters L, Rockstroh JK, Rakmanova A, Trofimova T, Lacombe K, Karpov I, Galli M, Domingo P, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord. Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals. AIDS. 2015 Jun 19;29(10):1205-15. doi: 10.1097/QAD.0000000000000674.

title: Liver-related death among HIV/hepatitis C virus-co-infected individuals

ReferenceCitation: Podlekareva DN, Panteleev AM, Grint D, Post FA, Miro JM, Bruyand M, Furrer H, Obel N, Girardi E, Vasilenko A, Losso MH, Arenas-Pinto A, Caylá J, Rakhmanova A, Zeltina I, Werlinrud AM, Lundgren JD, Mocroft A, Kirk O; HIV/TB study group. Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. Eur Respir J. 2014 Jan;43(1):166-77. doi: 10.1183/09031936.00138712. Epub 2013 Jun 13.

repository_institution: London School of Hygiene and Tropical Medicine - LSHTM Research Online

repositories_institution: London School of Hygiene and Tropical Medicine - LSHTM Research Online

title: Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe

ReferenceCitation: Ryom L, Mocroft A, Kirk O, Ross M, Reiss P, Fux CA, Morlat P, Moranne O, Smith C, El-Sadr W, Law M, Lundgren JD. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons. AIDS. 2014 Jan 14;28(2):187-99. doi: 10.1097/QAD.0000000000000042.

title: Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons

ReferenceCitation: Zoufaly A, Cozzi-Lepri A, Reekie J, Kirk O, Lundgren J, Reiss P, Jevtovic D, Machala L, Zangerle R, Mocroft A, Van Lunzen J; EuroSIDA in EuroCoord. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. PLoS One. 2014 Jan 31;9(1):e87160. doi: 10.1371/journal.pone.0087160. eCollection 2014.

title: Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe

ReferenceCitation: Grint D, Peters L, Rockstroh JK, de Wit S, Mitsura VM, Knysz B, Pedersen C, Kirk O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord. Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis. AIDS. 2014 Feb 20;28(4):577-87. doi: 10.1097/QAD.0000000000000069.

title: Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis

ReferenceCitation: Mocroft A, Ryom L, Reiss P, Furrer H, D'Arminio Monforte A, Gatell J, de Wit S, Beniowski M, Lundgren JD, Kirk O; EuroSIDA in EuroCOORD. A comparison of estimated glomerular filtration rates using Cockcroft-Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infection. HIV Med. 2014 Mar;15(3):144-52. doi: 10.1111/hiv.12095. Epub 2013 Oct 3.

name: Department of Infection and Population Health; University College London; London UK

name: Copenhagen HIV Program; University of Copenhagen; Copenhagen Denmark

name: Department of Infectious Diseases; Copenhagen University Hospital, Rigshospitalet; Copenhagen Denmark

name: Academisch Medisch Centrum bij de Universiteit van Amsterdam; Amsterdam The Netherlands

name: Infectious and Tropical Diseases Institute; Department of Health Sciences; San Paolo Hospital; University of Milan; Milan Italy

name: Hospital Clinic i Provincial; Barcelona Spain

name: HIV and AIDS Outpatient Clinic; Szpital Specjalistyczny; Chorzow Poland

repository_institution: Université Libre de Bruxelles - Dépôt institutionnel de l'Université libre de Bruxelles

repositories:
PubMed Central
Pure (Denmark)
UCL Discovery
dipot.ulb.ac.be

repositories_institution: Université Libre de Bruxelles - Dépôt institutionnel de l'Université libre de Bruxelles

title: A comparison of estimated glomerular filtration rates using Cockcroft−Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infection

ReferenceCitation: Shepherd L, Souberbielle JC, Bastard JP, Fellahi S, Capeau J, Reekie J, Reiss P, Blaxhult A, Bickel M, Leen C, Kirk O, Lundgren JD, Mocroft A, Viard JP; EuroSIDA in EuroCOORD. Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons. J Infect Dis. 2014 Jul 15;210(2):234-43. doi: 10.1093/infdis/jiu074. Epub 2014 Feb 3.

title: Prognostic Value of Vitamin D Level for All-cause Mortality, and Association With Inflammatory Markers, in HIV-infected Persons

ReferenceCitation: Mocroft A, Ryom L, Begovac J, Monforte AD, Vassilenko A, Gatell J, Florence E, Ormaasen V, Kirk O, Lundgren JD; EuroSIDA in EuroCOORD. Deteriorating renal function and clinical outcomes in HIV-positive persons. AIDS. 2014 Mar 13;28(5):727-37. doi: 10.1097/QAD.0000000000000134.

title: Deteriorating renal function and clinical outcomes in HIV-positive persons

ReferenceCitation: Kamara DA, Ryom L, Ross M, Kirk O, Reiss P, Morlat P, Moranne O, Fux CA, Mocroft A, Sabin C, Lundgren JD, Smith CJ; D:A:D study Group. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. BMC Nephrol. 2014 Mar 25;15:51. doi: 10.1186/1471-2369-15-51.

repository_institution: University of Groningen / Centre for Information Technology - University of Groningen research database

repositories_institution: University of Groningen / Centre for Information Technology - University of Groningen research database

title: Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study

ReferenceCitation: Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla PG, Guest J, Samji H, Castagna A, d'Arminio Monforte A, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher HC, De Wit S, Burkholder GA, Teira R, Justice AC, Sterling TR, M Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle SM, Sterne J, Obel N; Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis. 2014 May;58(9):1312-21. doi: 10.1093/cid/ciu038. Epub 2014 Jan 22.

name: Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital

name: Department of Microbiological Diagnostics and Virology, Statens Serum Institut, Copenhagen, Denmark

name: Department of Dermatology and Venerology, Innsbruck Medical University, Austria

name: Blood Centre and National Reference Centre for Congenital Bleeding Disorders, Laiko General Hospital, Athens, Greece

name: University Bordeaux, ISPED, Centre Inserm U897- Epidemiologie-Biostatistique, Bordeaux, France

name: Academic Medical Center, Department of Global Health, Amsterdam

name: Stichting HIV Monitoring, Amsterdam, The Netherlands

name: Department of Medicine, University of Calgary, Alberta, Canada

name: Research Department of Infection and Population Health, University College London

name: Department of Paediatric Infectious Diseases and Immunology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom

name: First Department of Internal Medicine, University of Cologne, Germany

name: Infectious Diseases Unit, Hospital General Universitario de Elche, Universidad Miguel Hernández, Alicante, Spain

name: Infectious Diseases Department and HIV Clinical Research Unit, Hotel Dieu University Hospital, Nantes, France

name: Copenhagen HIV Programme, Panum Institute, University of Copenhagen, Denmark

name: L'Institut National de la Santé et de la Recherche Médicale (INSERM), Unité Mixte de Recherche en Santé 943, University Pierre and Marie Curie, Hospital Pitie-Salpetriere, Paris, France

name: Department of Infectious Disease, Goethe University Hospital, Frankfurt/Main, Germany

name: Epidemiology Service, Public Health Agency of Barcelona, Spain

name: Atlanta Veterans Affairs Medical Center, Georgia

name: British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada

name: Department of Infectious and Tropical Diseases, San Raffaele Scientiﬁc Institute

name: Infectious Diseases Unit, Department of Health Sciences, San Paolo University Hospital, Milan, Italy

name: Competence Network for HIV/AIDS, Ruhr-Universität Bochum, Germany

name: Pediatrics Department, Hospital Universitario de Getafe, Madrid, Spain

name: Division of Infectious Diseases, Department of Internal Medicine, “San Gerardo” Hospital, University of Milan-Bicocca, Monza

name: Clinic of Infectious Diseases, Department of Internal Medicine, Medical Specialties University of Modena and Reggio Emilia, Italy

name: Infectious Diseases Unit, Hospital de Mataró, Barcelona, Spain

name: Service d'Epidémiologie et de Santé Publique, Hôpital de Bicêtre, AP-HP; INSERM U1018; Université Paris-Sud, France

name: Research Department of Infection and Population Health, University College London, United Kingdom

name: INSERM, CESP Centre for Research in Epidemiology and Population Health, Epidemiology of HIV and STI Team, Université Paris-Sud, Le Kremlin Bicêtre, France

name: Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Switzerland

name: Department of Infectious Diseases, St Pierre University Hospital, Brussels, Belgium

name: Division of Infectious Diseases, University of Alabama at Birmingham

name: Servicio de Medicina Interna, Hospital de Sierrallana Torrelavega, Cantabria, Spain

name: Veterans Affairs Connecticut Healthcare System, West Haven

name: Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut

name: Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee

name: Clinical Epidemiology and Health Services Research Core, Center for AIDS Research, University of Washington, Seattle

name: School of Social and Community Medicine, University of Bristol, United Kingdom

name: for the Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord

repository_institution: University of Bristol - Bristol Research

repositories_institution: University of Bristol - Bristol Research

title: Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery

ReferenceCitation: Petoumenos K, Reiss P, Ryom L, Rickenbach M, Sabin CA, El-Sadr W, d'Arminio Monforte A, Phillips AN, De Wit S, Kirk O, Dabis F, Pradier C, Lundgren JD, Law MG; D:A:D study group. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations. HIV Med. 2014 Nov;15(10):595-603. doi: 10.1111/hiv.12162. Epub 2014 May 19.

name: AHOD; The Kirby Institute; UNSW Australia; Sydney NSW Australia

name: Academic Medical Center; Department of Global Health; Amsterdam Institute for Global Health and Development; University of Amsterdam; Amsterdam The Netherlands

name: HIV Monitoring Foundation (ATHENA cohort); Amsterdam The Netherlands

name: Copenhagen HIV Program (CHIP); Department of Infectious Disease (8632); Rigshospitalet; University of Copenhagen; Copenhagen Denmark

name: Swiss HIV Cohort Study; Institute of Social and Preventive Medicine; University of Lausanne; Lausanne Switzerland

name: Research Department of Infection and Population Health; UCL; London UK

name: CPCRA; ICAP-Columbia University; New York USA

name: Infectious Diseases Unit; Department of Health Sciences; San Paolo University Hospital; Milan Italy

name: Saint-Pierre Cohort; CHU Saint-Pierre Hospital; Brussels Belgium

name: Univ. Bordeaux; ISPED; Centre Inserm U897 - Epidemiologie-Biostatistique; Bordeaux France

name: INSERM; ISPED; Centre Inserm U897 - Epidemiologie-Biostatistique; Bordeaux France

name: Department of Public Health; Nice University Hospital; Nice France

title: Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations

ReferenceCitation: Peters L, Mocroft A, Soriano V, Rockstroh JK, Kirkby N, Reiss P, Katlama C, Zakharova N, Flisiak R, Lundgren JD; EuroSIDA in EuroCoord. High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance. HIV Med. 2014 Nov;15(10):615-20. doi: 10.1111/hiv.12160. Epub 2014 May 11.

name: CHIP - Department of Infectious Diseases and Rheumatology; section 2100; Rigshospitalet; University of Copenhagen; Copenhagen Denmark

name: Royal Free Campus; University College Medical School; London UK

name: Department of Infectious Diseases; Hospital Carlos III; Madrid Spain

name: Department of Clinical Microbiology; Rigshospitalet; Copenhagen Denmark

name: Academic Medical Center; University of Amsterdam; Amsterdam The Netherlands

name: Hopital de la Pitié-Salpêtriére; Paris France

name: Department of Infectious Diseases; Medical University of Bialystok; Bialystok Poland

title: High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance

ReferenceCitation: Natural History Project Working Group for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naive individuals. AIDS. 2014 Jun 1;28(9):1351-6. doi: 10.1097/QAD.0000000000000224.

repository_institution: University of Portsmouth - Portsmouth Research Portal

repositories_institution: University of Portsmouth - Portsmouth Research Portal

title: Factors associated with short-term changes in HIV viral load and CD4+ cell count in antiretroviral-naive individuals

ReferenceCitation: Ingle SM, May MT, Gill MJ, Mugavero MJ, Lewden C, Abgrall S, Fätkenheuer G, Reiss P, Saag MS, Manzardo C, Grabar S, Bruyand M, Moore D, Mocroft A, Sterling TR, D'Arminio Monforte A, Hernando V, Teira R, Guest J, Cavassini M, Crane HM, Sterne JA; Antiretroviral Therapy Cohort Collaboration. Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Clin Infect Dis. 2014 Jul 15;59(2):287-97. doi: 10.1093/cid/ciu261. Epub 2014 Apr 24.

name:
School
        of Social and Community Medicine, University of Bristol, United Kingdom

name: Division of Infectious Diseases, University of Calgary, Canada

name: Division of Infectious Disease, Department of Medicine, University of Alabama, Birmingham

name: INSERM, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux

name: Université Bordeaux, Institut de Santé Publique, d'Epidémiologie et de Developpement (ISPED)

name: Service des maladies infectieuses et tropicales, AP-HP, Hôpital Avicenne, Bobigny, France

name: Department of Internal Medicine, University of Cologne, Germany

name: Stichting HIV Monitoring, and Division of Infectious Diseases and Department of Global Health, Amsterdam Institute for Global Health and Development, Academic Medical Center, University of Amsterdam, The Netherlands

name: Infectious Diseases Service, Hospital Clinic–IDIBAPS, Barcelona, Spain

name: AP-HP, Hôpital Cochin, Unité de Biostatistique et Epidémiologie, Paris

name: INSERM, ISPED, Centre Inserm U897-Epidemiologie-Biostatistique, Bordeaux, France

name: BC Centre for Excellence in HIV/AIDS, Department of Medicine, University of British Columbia, Vancouver, Canada

name: Vanderbilt University School of Medicine, Nashville, Tennessee

name: Clinic of Infectious Diseases and Tropical Medicine, San Paolo Hospital, University of Milan, Italy

name: Red de Investigación en Sida, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid

name: CIBER de Epidemiología y Salud Pública, Madrid

name: Unit of Infectious Diseases, Hospital Sierrallana, Torrelavega, Spain

name: Veterans Affairs Medical Center, Decatur, Georgia

name: Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Switzerland

name: for the Antiretroviral Therapy Cohort Collaboration

repository_institution: Red Federada de Repositorios Institucionales de Publicaciones Científicas - LA Referencia

repositories_institution: Red Federada de Repositorios Institucionales de Publicaciones Científicas - LA Referencia

title: Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients

ReferenceCitation: Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014 Jul 19;384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8.

title: Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration

ReferenceCitation: Mocroft A, Reiss P, Rakhmanova A, Banhegyi D, Phillips AN, De Wit S, Ristola M, Lundgren JD, Grarup J, Kirk O; EuroSIDA in EuroCOORD. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. Infection. 2014 Aug;42(4):757-62. doi: 10.1007/s15010-014-0630-4. Epub 2014 Jun 6.

title: A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

ReferenceCitation: Socio-economic Inequalities and HIV Writing Group for Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord, Lodi S, Dray-Spira R, Touloumi G, Braun D, Teira R, D'Arminio Monforte A, Gallois A, Zangerle R, Spire B, Dabis F, Stähelin C, Termote M, Kirk O, Chêne G, Egger M, del Amo J. Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord. AIDS. 2014 Sep 24;28(15):2297-306. doi: 10.1097/QAD.0000000000000410.

repository_institution: University of Bern - Bern Open Repository and Information System

repositories_institution: University of Bern - Bern Open Repository and Information System

title: Delayed HIV diagnosis and initiation of antiretroviral therapy

ReferenceCitation: Klein MB, Young J, Dunn D, Ledergerber B, Sabin C, Cozzi-Lepri A, Dabis F, Harrigan R, Tan DH, Walmsley S, Gill J, Cooper C, Scherrer AU, Mocroft A, Hogg RS, Smaill F; Canadian-European Clade Collaboration. The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study. CMAJ Open. 2014 Oct 1;2(4):E318-29. doi: 10.9778/cmajo.20140017. eCollection 2014 Oct.

name: for the Canadian-European Clade Collaboration

title: The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study

ReferenceCitation: Borges ÁH, Lundgren JD, Ridolfo A, Katlama C, Antunes F, Grzeszczuk A, Blaxhult A, Mitsura VM, Doroana M, Battegay M, Gargalianos P, Mocroft A; EuroSIDA in EuroCOORD. Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. AIDS. 2014 Nov 13;28(17):2565-71. doi: 10.1097/QAD.0000000000000433.

title: Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease

ReferenceCitation: Cozzi-Lepri A, Noguera-Julian M, Di Giallonardo F, Schuurman R, Däumer M, Aitken S, Ceccherini-Silberstein F, D'Arminio Monforte A, Geretti AM, Booth CL, Kaiser R, Michalik C, Jansen K, Masquelier B, Bellecave P, Kouyos RD, Castro E, Furrer H, Schultze A, Günthard HF, Brun-Vezinet F, Paredes R, Metzner KJ; CHAIN Minority HIV-1 Variants Working Group. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing. J Antimicrob Chemother. 2015 Mar;70(3):930-40. doi: 10.1093/jac/dku426. Epub 2014 Oct 21.

name: Institut de Recerca de la SIDA IrsiCaixa i Unitat VIH, Universitat Autònoma de Barcelona, Universitat de Vic, Catalonia, Spain

name: Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland

name: Department of Virology, University Medical Centre, Utrecht, The Netherlands

name: Institut für Immunologie und Genetik, Kaiserslautern, Germany

name: Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy

name: Department of Health Sciences, Clinic of Infectious Diseases, ‘San Paolo’ Hospital, University of Milan, Milan, Italy

name: Institute of Infection & Global Health, University of Liverpool, Liverpool, UK

name: Department of Virology, Royal Free London NHS Foundation Trust, London, UK

name: Institute of Virology, University of Cologne, Cologne, Germany

name: Competence Network for HIV/AIDS, Bochum, Germany and Clinic for Dermatology, Venerology and Allergology of the Ruhr-Universität, Bochum, Germany

name: Clinical Trial Centre (ZKS), University of Cologne, Cologne, Germany

name: Laboratoire de Virologie, CHU de Bordeaux and MFP-UMR5234, Université Bordeaux 2, Bordeaux, France

name: Addiction Medicine, Service of Community Psychiatry, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

name: Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland

name: Department of Virology, Bichat University Hospital, Paris, France

name: on behalf of the CHAIN Minority HIV-1 Variants Working Group

repository_institution: Universitat Autònoma de Barcelona - Dipòsit Digital de Documents de la UAB

repositories_institution: Universitat Autònoma de Barcelona - Dipòsit Digital de Documents de la UAB

title: Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

ReferenceCitation: Søgaard OS, Reekie J, Ristola M, Jevtovic D, Karpov I, Beniowski M, Servitskiy S, Domingo P, Reiss P, Mocroft A, Kirk O. Severe bacterial non-aids infections in HIV-positive persons: incidence rates and risk factors. J Infect. 2013 May;66(5):439-46. doi: 10.1016/j.jinf.2012.12.012. Epub 2013 Jan 24.

title: Severe bacterial non-aids infections in HIV-positive persons: Incidence rates and risk factors

ReferenceCitation: Monforte Ad, Reiss P, Ryom L, El-Sadr W, Dabis F, De Wit S, Worm SW, Law MG, Weber R, Kirk O, Pradier C, Phillips AN, Lundgren JD, Sabin CA. Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events. AIDS. 2013 Jan 28;27(3):407-15. doi: 10.1097/QAD.0b013e32835b2ef1.

title: Atazanavir is not associated with an increased risk of cardio or cerebrovascular disease events

ReferenceCitation: Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, Nattermann J, Lampe FC, Bucher HC, Sterling TR, Crane HM, Kitahata MM, May M, Sterne JA. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS. 2013 Feb 20;27(4):563-72. doi: 10.1097/QAD.0b013e32835b8c7f.

title: An internationally generalizable risk index for mortality after one year of antiretroviral therapy

ReferenceCitation: Podlekareva DN, Grint D, Post FA, Mocroft A, Panteleev AM, Miller RF, Miro JM, Bruyand M, Furrer H, Riekstina V, Girardi E, Losso MH, Caylá JA, Malashenkov EA, Obel N, Skrahina AM, Lundgren JD, Kirk O; HIV-TB Study Group. Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients. Int J Tuberc Lung Dis. 2013 Feb;17(2):198-206. doi: 10.5588/ijtld.12.0224.

journal_name: The International Journal of Tuberculosis and Lung Disease

publisher: International Union Against Tuberculosis and Lung Disease

publisher_dissemination: International Union Against Tuberculosis and Lung Disease

publisher_group: International Union Against Tuberculosis and Lung Disease

publisher_normalized: International Union Against Tuberculosis and Lung Disease

title: Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients

ReferenceCitation: Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Costagliola D, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Touloumi G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Perez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Phillips A, Lodwick R, Torti C, Dorrucci M, Günthard HF, Michalik C, Chrysos G, Castagna A. Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes. J Infect Dis. 2013 Mar 1;207(5):759-67. doi: 10.1093/infdis/jis752. Epub 2012 Dec 7.

name: The Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)

title: Predictors of CD4+ T-Cell Counts of HIV Type 1–Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes

ReferenceCitation: Abgrall S, Ingle SM, May MT, Costagliola D, Mercie P, Cavassini M, Reekie J, Samji H, Gill MJ, Crane HM, Tate J, Sterling TR, Antinori A, Reiss P, Saag MS, Mugavero MJ, Phillips A, Manzardo C, Wasmuth JC, Stephan C, Guest JL, Gomez Sirvent JL, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC). Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. AIDS. 2013 Mar 13;27(5):803-13. doi: 10.1097/QAD.0b013e32835cb997. Erratum in: AIDS. 2014 Jul 31;28(12):1853.

title: Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002–2009

ReferenceCitation: Sabin CA, Ryom L, Kovari H, Kirk O, de Wit S, Law M, Reiss P, Dabis F, Pradier C, El-Sadr W, Monforte Ad, Kamara D, Phillips AN, Lundgren JD. Association between ALT level and the rate of cardio/cerebrovascular events in HIV-positive individuals: the D: A: D study. J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):456-63. doi: 10.1097/QAI.0b013e318291cd29.

title: Association Between ALT Level and the Rate of Cardio/Cerebrovascular Events in HIV-Positive Individuals

ReferenceCitation: Grint D, Peters L, Reekie J, Soriano V, Kirk O, Knysz B, Suetnov O, Lazzarin A, Ledergerber B, Rockstroh JK, Mocroft A; EuroSIDA in EuroCoord (European Coordinating Committee for the Integration of Ongoing Coordination Actions Related to Clinical and Epidemiological HIV Research). Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. HIV Med. 2013 Jul;14(6):370-8. doi: 10.1111/hiv.12033. Epub 2013 Mar 27.

name: Copenhagen HIV Programme; University of Copenhagen; Copenhagen; Denmark

name: Regional AIDS Centre; Svetlogorsk; Belarus

name: Division of Infectious Diseases and Hospital Epidemiology; University Hospital Zurich; University of Zurich; Zurich; Switzerland

title: Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy

ReferenceCitation: Mocroft A, Phillips AN, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Podlekareva D, Lundgren JD; EuroSIDA study in EuroCOORD. CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use. AIDS. 2013 Mar 27;27(6):907-918. doi: 10.1097/QAD.0b013e32835cb766.

title: CD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use

ReferenceCitation: Rockstroh JK, Peters L, Grint D, Soriano V, Reiss P, Monforte Ad, Beniowski M, Losso MH, Kirk O, Kupfer B, Mocroft A; EuroSIDA in EuroCoord. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? J Hepatol. 2013 Aug;59(2):213-20. doi: 10.1016/j.jhep.2013.04.005. Epub 2013 Apr 11.

title: Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?

ReferenceCitation: Ryom L, Kirk O, Lundgren JD, Reiss P, Pedersen C, De Wit S, Buzunova S, Gasiorowski J, Gatell JM, Mocroft A; EuroSIDA in EuroCoord. Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe. HIV Med. 2013 Sep;14(8):503-8. doi: 10.1111/hiv.12038. Epub 2013 Apr 16.

name: Copenhagen HIV Programme; Faculty of Health & Medical Sciences; University of Copenhagen; Copenhagen; Denmark

name: Academic Medical Center; University of Amsterdam; Amsterdam; The Netherlands

name: Department of Infectious Diseases; Odense University Hospital; Odense; Denmark

name: Department of Infectious Diseases; CHU Saint-Pierre; Brussels; Belgium

name: Novgorod Centre for AIDS; Novgorod; Russia

name: Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiencies; Wroclaw University School of Medicine; Wroclaw; Poland

name: Hospital Clinic Barcelona; University of Barcelona; Barcelona; Spain

name: Department of Infection and Population Health; University College London; London; UK

title: Advanced chronic kidney disease, end-stage renal disease and renal death among HIV-positive individuals in Europe

ReferenceCitation: Ryom L, Mocroft A, Kirk O, Worm SW, Kamara DA, Reiss P, Ross M, Fux CA, Morlat P, Moranne O, Smith C, Lundgren JD; D:A:D Study Group. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis. 2013 May 1;207(9):1359-69. doi: 10.1093/infdis/jit043. Epub 2013 Feb 4.

title: Association Between Antiretroviral Exposure and Renal Impairment Among HIV-Positive Persons With Normal Baseline Renal Function: the D:A:D Studya

ReferenceCitation: Peters L, Mocroft A, Soriano V, Rockstroh J, Rauch A, Karlsson A, Knysz B, Pradier C, Zilmer K, Lundgren JD; for EuroSIDA in EuroCoord. Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients. PLoS One. 2013 May 27;8(5):e64283. doi: 10.1371/journal.pone.0064283. Print 2013.

repository_institution: Goethe University Frankfurt - Publication Server of Goethe University Frankfurt am Main

repositories_institution: Goethe University Frankfurt - Publication Server of Goethe University Frankfurt am Main

title: Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients

ReferenceCitation: Kovari H, Sabin CA, Ledergerber B, Ryom L, Worm SW, Smith C, Phillips A, Reiss P, Fontas E, Petoumenos K, De Wit S, Morlat P, Lundgren JD, Weber R. Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study. Clin Infect Dis. 2013 Mar;56(6):870-9. doi: 10.1093/cid/cis919. Epub 2012 Oct 22.

title: Antiretroviral Drug-Related Liver Mortality Among HIV-Positive Persons in the Absence of Hepatitis B or C Virus Coinfection: The Data Collection on Adverse Events of Anti-HIV Drugs Study

ReferenceCitation: Mocroft A, Lundgren JD, Sabin ML, Monforte Ad, Brockmeyer N, Casabona J, Castagna A, Costagliola D, Dabis F, De Wit S, Fätkenheuer G, Furrer H, Johnson AM, Lazanas MK, Leport C, Moreno S, Obel N, Post FA, Reekie J, Reiss P, Sabin C, Skaletz-Rorowski A, Suarez-Lozano I, Torti C, Warszawski J, Zangerle R, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Kirk O; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med. 2013;10(9):e1001510. doi: 10.1371/journal.pmed.1001510. Epub 2013 Sep 3.

name: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord

repository_institution: Robert Kock Institute - Publication server of the Robert Koch Institute

repositories_institution: Robert Kock Institute - Publication server of the Robert Koch Institute

title: Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)

ReferenceCitation: Kaulich-Bartz J, Dam W, May MT, Lederberger B, Widmer U, Phillips AN, Grabar S, Mocroft A, Vilaro J, van Sighem A, Moreno S, Dabis F, Monforte AD, Teira R, Ingle SM, Sterne JA; Writing Committee for the Antiretroviral Therapy Cohort Collaboration. Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies. AIDS. 2013 Jun 19;27(10):1641-55. doi: 10.1097/QAD.0b013e3283601199.

title: Insurability of HIV-positive people treated with antiretroviral therapy in Europe

ReferenceCitation: Mocroft A, Furrer HJ, Miro JM, Reiss P, Mussini C, Kirk O, Abgrall S, Ayayi S, Bartmeyer B, Braun D, Castagna A, d'Arminio Monforte A, Gazzard B, Gutierrez F, Hurtado I, Jansen K, Meyer L, Muñoz P, Obel N, Soler-Palacin P, Papadopoulos A, Raffi F, Ramos JT, Rockstroh JK, Salmon D, Torti C, Warszawski J, de Wit S, Zangerle R, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Lundgren JD; Opportunistic Infections Working Group on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD. The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis. 2013 Oct;57(7):1038-47. doi: 10.1093/cid/cit423. Epub 2013 Aug 6.

name: Department of Infection and Population Health, University College London, United Kingdom

name: Department of Infectious Diseases, Bern University Hospital and University of Bern, Switzerland

name: Hospital Clinic–IDIBAPS, University of Barcelona, Spain

name: Academisch Medisch Centrum bij de Universiteit van Amsterdam

name: Department of Infectious Diseases, Copenhagen University Hospital/Rigshospitalet, Denmark

name: AP-HP, Hôpital Avicenne, Services des Maladies Infectieuses et Tropicales, Paris

name: CHU de Bordeaux and INSERM U897, Bordeaux, France

name: Department of Infectious Disease, Robert Koch-Institute, Berlin, Germany

name: Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland

name: Department of Infectious Diseases IRCCS San Raffaele

name: Department of Health Sciences, Institute of Infectious Diseases, Milan, Italy

name: St Stephen's Clinic, Chelsea and Westminster Hospital, London, United Kingdom

name: Infectious Diseases Unit, Hospital General Universitario de Elche, Universidad Miguel Hernández, Alicante

name: Centro Superior de Investigación en Salud Pública (CSISP-FISABIO), Red de Investigacion en Servicios de Salud en Enfermedades Cronicas (REDISSEC), Valencia, Spain

name: Competence Network for HIV/AIDS, St Josef-Clinic, Ruhr-University, Bochum, Germany

name: CESP Centre for Research in Epidemiology and Population Health, INSERM U1018, Paris

name: Epidemiology and Public Health Service, AP-HP, Hopital Bicêtre, Le Kremlin Bicêtre, France

name: Departament of Infectious Diseases, Hospital Universitario de Basurto, Bilbao

name: Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain

name: University of Athens Medical School, University General Hospital “ATTIKON,” Greece

name: University Hospital, Hotel Dieu, Nantes, France

name: Hospital Universitario de Getafe, Madrid, Spain

name: Medizinische Universitäts Klinik I, University of Bonn, Germany

name: Department of Internal Medicine and Infectious Diseases, Cochin Hospital, Paris, France

name: University Division of Infectious and Tropical Diseases, University and Spedali Civili of Brescia

name: Department of Medical and Surgical Sciences, Unit of Infectious Diseases, University “Magna Graecia,” Catanzaro, Italy

name: AP-HP Public Health Department, INSERM CESP U1018, Université Paris-Sud, Le Kremlin-Bicêtre, France

name: Saint-Pierre Hospital, Brussels, Belgium

name: Centre INSERM U897-Epidémiologie Statistique, Université de Bordeaux, ISPED

name: INSERM, ISPED, Centre INSERM U897-Epidémiologie Statistique, Bordeaux, France

name: for the Opportunistic Infections Working Group on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCOORD

title: The Incidence of AIDS-Defining Illnesses at a Current CD4 Count ≥200 Cells/µL in the Post–Combination Antiretroviral Therapy Era

ReferenceCitation: Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fätkenheuer G, d'Arminio Monforte A, Abrams DI, Grulich A, Fontas E, Kirk O, Furrer H, De Wit S, Phillips A, Lundgren JD, Sabin CA; D:A:D Study Group. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study. BMC Infect Dis. 2013 Oct 9;13:471. doi: 10.1186/1471-2334-13-471.

repository_institution: University of California - eScholarship University of California

repositories_institution: University of California - eScholarship University of California

title: Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study

ReferenceCitation: May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, D'Arminio Monforte A, Casabona J, Hogg RS, Mocroft A, Lampe FC, Dabis F, Fätkenheuer G, Sterling TR, del Amo J, Gill MJ, Crane HM, Saag MS, Guest J, Brodt HR, Sterne JA; Antiretroviral Cohort Collaboration. Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). Int J Epidemiol. 2014 Jun;43(3):691-702. doi: 10.1093/ije/dyt010. Epub 2013 Apr 18.

repositories_institution:
PubMed Central - Europe PMC
Université de Lausanne - SERVAL
reroDoc Digital Library

title: Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC)

ReferenceCitation: Post FA, Grint D, Werlinrud AM, Panteleev A, Riekstina V, Malashenkov EA, Skrahina A, Duiculescu D, Podlekareva D, Karpov I, Bondarenko V, Chentsova N, Lundgren J, Mocroft A, Kirk O, Miro JM; HIV-TB Study Group. Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe. J Infect. 2014 Mar;68(3):259-63. doi: 10.1016/j.jinf.2013.09.034. Epub 2013 Nov 16.

title: Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe

ReferenceCitation: Efsen AM, Panteleev AM, Grint D, Podlekareva DN, Vassilenko A, Rakhmanova A, Zeltina I, Losso MH, Miller RF, Girardi E, Caylá J, Post FA, Miro JM, Bruyand M, Furrer H, Obel N, Lundgren JD, Mocroft A, Kirk O; HIV/TB Study Group. TB meningitis in HIV-positive patients in Europe and Argentina: clinical outcome and factors associated with mortality. Biomed Res Int. 2013;2013:373601. doi: 10.1155/2013/373601. Epub 2013 Dec 31.

name: Copenhagen HIV Programme, Rigshospitalet, Faculty of Health and Medical Sciences, Copenhagen University Hospital and University of Copenhagen, 2200 Copenhagen N, Denmark

name: TB Hospital No. 2, Russian Federation, 195267 Saint Petersburg, Russia

name: University College London, Royal Free Campus, London NW3 2PF, UK

name: Belorusian State Medical University, Minsk 220002, Belarus

name: St. Petersburg AIDS Centre, 193167 Saint Petersburg, Russia

name: Infectology Centre of Latvia, 1006 Riga, Latvia

name: Hospital JM Ramos Mejia, Servicio de Inmunocomprometidos, CP 1221 Buenos Aires, Argentina

name: Centre for Sexual Health & HIV Research, Mortimer Market Centre, University College London, London WC1E 6JB, UK

name: Istituto Nazionale Malattie Infettive L Spallanzani, 00149 Rome, Italy

name: Servicio de Epidemiología, Agencia de Salud Pública de Barcelona, CIBER Epidemiología y Salud Pública (CIBERESP), 08 036 Barcelona, Spain

name: King’s College London School of Medicine, London SE5 9RS, UK

name: Hospital Clinic-IDIBAPS, University of Barcelona, 08 036 Barcelona, Spain

name: Centre Hospitalier Universitaire (CHU) de Bordeaux, COREVIH Aquitaine, 33000 Bordeaux, France

name: INSERM, ISPED, Centre Inserm U897-Epidemiologie-Biostatistique, 33000 Bordeaux, France

name: Department of Infectious Diseases, Bern University Hospital and University of Bern, CH-3010 Bern, Switzerland

name: Department of Infectious Diseases, Copenhagen University Hospital/Rigshospitalet, 2100 Copenhagen, Denmark

repositories:
PubMed Central
UCL Discovery
pdfs.semanticscholar.org

title: TB Meningitis in HIV-Positive Patients in Europe and Argentina: Clinical Outcome and Factors Associated with Mortality

ReferenceCitation: Sabin CA, Ryom L, De Wit S, Mocroft A, Phillips AN, Worm SW, Weber R, D'Arminio Monforte A, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J; D:A:D Study Group. Associations between immune depression and cardiovascular events in HIV infection. AIDS. 2013 Nov 13;27(17):2735-48. doi: 10.1097/01.aids.0000432457.91228.f3.

title: Associations between immune depression and cardiovascular events in HIV infection

ReferenceCitation: Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, d'Arminio Monforte A, Phillips A, Lundgren JD, Kirk O; EuroSIDA study group. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. AIDS. 2012 Jan 28;26(3):315-23. doi: 10.1097/QAD.0b013e32834e8805.

title: Long-term exposure to combination antiretroviral therapy and risk of death from specific causes

ReferenceCitation: Pursuing Later Treatment Option II (PLATO II) project team; Observational HIV Epidemiological Research Europe (COHERE) Group, Costagliola D, Lodwick R, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Touoloumi G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Pérez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chene G, Grarup J, Phillips A. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis. 2012 Feb;12(2):119-27. doi: 10.1016/S1473-3099(11)70248-1. Epub 2011 Oct 9.

title: Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study

ReferenceCitation: Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, Grzeszczuk A, Sambatakou H, Mocroft A, Kirk O; EuroSIDA in EuroCoord. Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. AIDS. 2012 Sep 24;26(15):1917-26.

ReferenceCitation: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord, Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, van Sighem A, Kirk O, Obel N, Panos G, Ghosn J, Dabis F, Mary-Krause M, Leport C, Perez-Hoyos S, Sobrino-Vegas P, Stephan C, Castagna A, Antinori A, d'Arminio Monforte A, Torti C, Mussini C, Isern V, Calmy A, Teira R, Egger M, Grarup J, Chêne G. All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol. 2012 Apr;41(2):433-45. doi: 10.1093/ije/dyr164. Epub 2011 Nov 28.

name: The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord

title: All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaboration

ReferenceCitation: Worm SW, Kamara DA, Reiss P, Fontas E, De Wit S, El-Sadr W, D'Arminio Monforte A, Law M, Phillips A, Ryom L, Dabis F, Weber R, Sabin C, Lundgren JD; D:A:D Study Group. Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke. J Infect Dis. 2012 Feb 15;205(4):535-9. doi: 10.1093/infdis/jir788. Epub 2012 Jan 5.

title: Evaluation of HIV Protease Inhibitor Use and the Risk of Sudden Death or Nonhemorrhagic Stroke

ReferenceCitation: Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Møller N, Lundgren JD, Law MG; D:A:D Study Group. Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. J Int AIDS Soc. 2012 Oct 10;15(2):17426. doi: 10.7448/IAS.15.2.17426.

repository_institution: Columbia University - Columbia Academic Commons

repositories_institution: Columbia University - Columbia Academic Commons

title: Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study

ReferenceCitation: Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord, Young J, Psichogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, Reiss P, Gazzard B, Sharland M, Gutierrez F, Obel N, Kirk O, Miro JM, Furrer H, Castagna A, De Wit S, Muñoz J, Kjaer J, Grarup J, Chêne G, Bucher H. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med. 2012;9(3):e1001194. doi: 10.1371/journal.pmed.1001194. Epub 2012 Mar 20.

name: The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord

repository_institution: University Library Bern - BORIS - Bern Open Repository and Information System

repository_institution: St George's University of London - St George's Online Research Archive

repositories_institution: St George's University of London - St George's Online Research Archive

repositories_institution: University Library Bern - BORIS - Bern Open Repository and Information System

title: CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE

ReferenceCitation: Mocroft A, Bannister WP, Kirk O, Kowalska JD, Reiss P, D'Arminio-Monforte A, Gatell J, Fisher M, Trocha H, Rakhmanova A, Lundgren JD; EuroSIDA Study in EuroCOORD. The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression. Antivir Ther. 2012;17(7):1291-300. doi: 10.3851/IMP2407. Epub 2012 Sep 26.

title: The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression

ReferenceCitation: HCV working group of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord. Effect of hepatitis C treatment on CD4+ T-cell counts and the risk of death in HIV-HCV-coinfected patients: the COHERE collaboration. Antivir Ther. 2012;17(8):1541-50. doi: 10.3851/IMP2263. Epub 2012 Jul 24.

name: The HCV working group of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord

title: Effect of hepatitis C treatment on CD4 cell counts and the risk of death in HIV-hepatitis C co-infected patients; COHERE collaboration

ReferenceCitation: May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC). Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. Int J Epidemiol. 2012 Dec;41(6):1807-20. doi: 10.1093/ije/dys164. Epub 2012 Nov 12.

title: Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics

ReferenceCitation: Murray M, Hogg RS, Lima VD, May MT, Moore DM, Abgrall S, Bruyand M, D'Arminio Monforte A, Tural C, Gill MJ, Harris RJ, Reiss P, Justice A, Kirk O, Saag M, Smith CJ, Weber R, Rockstroh J, Khaykin P, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC). The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Med. 2012 Feb;13(2):89-97. doi: 10.1111/j.1468-1293.2011.00940.x. Epub 2011 Aug 7.

name: for the Antiretroviral Therapy Cohort Collaboration (ART-CC)

title: The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis

ReferenceCitation: Bannister WP, Cozzi-Lepri A, Kjær J, Clotet B, Lazzarin A, Viard JP, Kronborg G, Duiculescu D, Beniowski M, Machala L, Phillips A; EuroSIDA group. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. J Antimicrob Chemother. 2011 Apr;66(4):901-11. doi: 10.1093/jac/dkr006. Epub 2011 Jan 31.

title: Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

ReferenceCitation: Petoumenos K, Worm S, Reiss P, de Wit S, d'Arminio Monforte A, Sabin C, Friis-Møller N, Weber R, Mercie P, Pradier C, El-Sadr W, Kirk O, Lundgren J, Law M; D:A:D Study Group. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*). HIV Med. 2011 Aug;12(7):412-21. doi: 10.1111/j.1468-1293.2010.00901.x. Epub 2011 Jan 20.

title: Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study*

ReferenceCitation: Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG, Horban A, Domingo P, Mocroft A, Lundgren JD, Kirk O; EuroSIDA study group. Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors. AIDS. 2011 Jul 31;25(12):1505-13. doi: 10.1097/QAD.0b013e328348fafd.

title: Tuberculosis among HIV-positive patients across Europe

ReferenceCitation: Bohlius J, Schmidlin K, Boué F, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Paparizos V, Miro JM, Obel N, Prins M, Chêne G, Egger M; Collaboration of Observational HIV Epidemiological Research Europe. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4⁺ T-cell lymphocytes. Blood. 2011 Jun 9;117(23):6100-8. doi: 10.1182/blood-2010-08-301531. Epub 2011 Mar 2.

name: Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland;

name: Medecine Interne et Immunologie Clinique, Hopital Antoine Beclere, Assistance Publique-Hopitaux de Paris, Université Paris Sud, Clamart, France;

name: First Department of Internal Medicine, University of Cologne, Cologne, Germany;

name: School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom;

name: Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain;

name: HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, Division of Population Health, University College London Medical School, London, United Kingdom;

name: Inserm U897, Université Victor Segalen Bordeaux, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France;

name: International Agency for Research on Cancer, Lyon, France;

name: AIDS Unit, Clinic of Venerologic & Dermatologic Diseases, Athens University Medical School, Syngros Hospital, Athens, Greece;

name: Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;

name: Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Denmark;

name: Academic Medical Center, University of Amsterdam, The Netherlands; and

name: Institut de Santé Publique, d'Epidémiologie et de Développement, Université Victor Segalen, Bordeaux, France

name: Collaboration of Observational HIV Epidemiological Research Europe

title: HIV-1–related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes

ReferenceCitation: Kowalska JD, Friis-Møller N, Kirk O, Bannister W, Mocroft A, Sabin C, Reiss P, Gill J, Lewden C, Phillips A, D'Arminio Monforte A, Law M, Sterne J, De Wit S, Lundgren JD; CoDe Working Group; D:A:D Study Group. The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology. 2011 Jul;22(4):516-23. doi: 10.1097/EDE.0b013e31821b5332.

title: The Coding Causes of Death in HIV (CoDe) Project

ReferenceCitation: Soriano V, Grint D, d'Arminio Monforte A, Horban A, Leen C, Poveda E, Antunes F, de Wit S, Lundgren J, Rockstroh J, Peters L. Hepatitis delta in HIV-infected individuals in Europe. AIDS. 2011 Oct 23;25(16):1987-92. doi: 10.1097/QAD.0b013e32834babb3.

title: Hepatitis delta in HIV-infected individuals in Europe

ReferenceCitation: Reekie J, Gatell JM, Yust I, Bakowska E, Rakhmanova A, Losso M, Krasnov M, Francioli P, Kowalska JD, Mocroft A; EuroSIDA in EuroCoord. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata. AIDS. 2011 Nov 28;25(18):2259-68. doi: 10.1097/QAD.0b013e32834cdb4b.

title: Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata

ReferenceCitation: Paredes R, Puertas MC, Bannister W, Kisic M, Cozzi-Lepri A, Pou C, Bellido R, Betancor G, Bogner J, Gargalianos P, Bánhegyi D, Clotet B, Lundgren J, Menéndez-Arias L, Martinez-Picado J; EuroSIDA Study Group. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy. J Infect Dis. 2011 Sep 1;204(5):741-52. doi: 10.1093/infdis/jir385.

name: Institut de Recerca de la SIDA–IrsiCaixa

name: Lluita Contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain

name: Research Department of Infection & Population Health, University College London, United Kingdom

name: Centro de Biología Molecular “Severo Ochoa” (CSIC-UAM), Madrid, Spain

name: Medizinische Poliklinik, Munich, Germany

name: Special Infectious Unit/First Department of Medicine, Athens General Hospital, Greece

name: Immunology Department, Szent Lszl Hospital, Budapest, Hungary

name: Copenhagen HIV Programme, University of Copenhagen

name: Department of Infectious Diseases, Centre for Viral Disease KMA, Rigshospitalet, Copenhagen, Denmark

name: Institució Catalana de Recerca Avançada (ICREA), Barcelona, Spain

title: A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy

ReferenceCitation: Cozzi-Lepri A, Prosperi MC, Kjær J, Dunn D, Paredes R, Sabin CA, Lundgren JD, Phillips AN, Pillay D; EuroSIDA Study; United Kingdom CHIC/United Kingdom HDRD Study. Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score. PLoS One. 2011;6(11):e25665. doi: 10.1371/journal.pone.0025665. Epub 2011 Nov 16.

name: for the EuroSIDA and the United Kingdom CHIC/United Kingdom HDRD Studies

repository_institution: The University of Manchester - Research Explorer

repositories:
PubMed Central
Pure (Denmark)
UCL Discovery
pdfs.semanticscholar.org

repositories_institution: The University of Manchester - Research Explorer

title: Can Linear Regression Modeling Help Clinicians in the Interpretation of Genotypic Resistance Data? An Application to Derive a Lopinavir-Score

ReferenceCitation: Cozzi-Lepri A, Paredes, Phillips AN, Clotet B, Kjaer J, Von Wyl V, Kronborg G, Castagna A, Bogner JR, Lundgren JD; EuroSIDA in EuroCoord. The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*. HIV Med. 2012 Jan;13(1):62-72. doi: 10.1111/j.1468-1293.2011.00943.x. Epub 2011 Aug 17.

title: The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*

ReferenceCitation: Worm SW, Kamara DA, Reiss P, Kirk O, El-Sadr W, Fux C, Fontas E, Phillips A, D'Arminio Monforte A, De Wit S, Petoumenos K, Friis-Mller N, Mercie P, Lundgren JD, Sabin C. Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS. 2011 Jul 31;25(12):1497-504. doi: 10.1097/QAD.0b013e32834917c6.

title: Elevated triglycerides and risk of myocardial infarction in HIV-positive persons

ReferenceCitation: Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. The impact of fasting on the interpretation of triglyceride levels for predicting myocardial infarction risk in HIV-positive individuals: the D:A:D study. J Infect Dis. 2011 Aug 15;204(4):521-5. doi: 10.1093/infdis/jir329.

name: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study

title: The Impact of Fasting on the Interpretation of Triglyceride Levels for Predicting Myocardial Infarction Risk in HIV-Positive Individuals: The D:A:D Study

ReferenceCitation: Pursuing Later Treatment Options II (PLATO II) project team; Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Group, Nakagawa F, Lodwick R, Costagliola D, van Sighem A, Torti C, Podzamczer D, Mocroft A, Ledergerber B, Dorrucci M, Cozzi-Lepri A, Jansen K, Masquelier B, García F, De Wit S, Stephan C, Obel N, Fätkenhaeuer G, Castagna A, Sambatakou H, Mussini C, Ghosn J, Zangerle R, Duval X, Meyer L, Perez-Hoyos S, Fabre Colin C, Kjaer J, Chene G, Grarup J, Phillips A. Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):294-9. doi: 10.1097/QAI.0b013e31823fe66b.

title: Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe

ReferenceCitation: Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, Kücherer C, Obel N, von Wyl V, Masquelier B, Stephan C, Torti C, Antinori A, García F, Judd A, Porter K, Thiébaut R, Castro H, van Sighem AI, Colin C, Kjaer J, Lundgren JD, Paredes R, Pozniak A, Clotet B, Phillips A, Pillay D, Chêne G; EuroCoord-CHAIN study group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011 May;11(5):363-71. doi: 10.1016/S1473-3099(11)70032-9. Epub 2011 Feb 25.

title: Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study

ReferenceCitation: Reekie J, Mocroft A, Ledergerber B, Beniowski M, Clotet B, van Lunzen J, Chiesi A, Pradier C, Machala L, Lundgren JD; EuroSIDA Study Group. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change. HIV Med. 2010 Aug;11(7):469-78. doi: 10.1111/j.1468-1293.2009.00816.x. Epub 2010 Feb 22.

title: History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change

ReferenceCitation: Soriano V, Mocroft A, Peters L, Rockstroh J, Antunes F, Kirkby N, de Wit S, Monforte Ad, Flisiak R, Lundgren J; EuroSIDA. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. J Antimicrob Chemother. 2010 Mar;65(3):548-55. doi: 10.1093/jac/dkp479. Epub 2010 Jan 5.

title: Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe

ReferenceCitation: Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Lodwick R, Costagliola D, Reiss P, Torti C, Teira R, Dorrucci M, Ledergerber B, Mocroft A, Podzamczer D, Cozzi-Lepri A, Obel N, Masquelier B, Staszewski S, García F, De Wit S, Castagna A, Antinori A, Judd A, Ghosn J, Touloumi G, Mussini C, Duval X, Ramos J, Meyer L, Warsawski J, Thorne C, Masip J, Pérez-Hoyos S, Pillay D, van Sighem A, Lo Caputo S, Günthard H, Paredes R, De Luca A, Paraskevis D, Fabre-Colin C, Kjaer J, Chêne G, Lundgren JD, Phillips AN. Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med. 2010 Mar 8;170(5):410-9. doi: 10.1001/archinternmed.2009.472.

name: The Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)

title: Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years

ReferenceCitation: Reekie J, Kosa C, Engsig F, Monforte Ad, Wiercinska-Drapalo A, Domingo P, Antunes F, Clumeck N, Kirk O, Lundgren JD, Mocroft A; EuroSIDA Study Group. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer. 2010 Nov 15;116(22):5306-15. doi: 10.1002/cncr.25311.

title: Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies

ReferenceCitation: Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, Beniowski M, Gatell J, Phillips AN, Ledergerber B, Lundgren JD; EuroSIDA Study Group. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS. 2010 Jul 17;24(11):1667-78. doi: 10.1097/QAD.0b013e328339fe53.

title: Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

ReferenceCitation: Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010 May 15;50(10):1387-96. doi: 10.1086/652283.

title: Causes of Death in HIV‐1–Infected Patients Treated with Antiretroviral Therapy, 1996–2006: Collaborative Analysis of 13 HIV Cohort Studies

ReferenceCitation: Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), Mocroft A, Reiss P, Kirk O, Mussini C, Girardi E, Morlat P, Stephan C, De Wit S, Doerholt K, Ghosn J, Bucher HC, Lundgren JD, Chene G, Miro JM, Furrer H. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clin Infect Dis. 2010 Sep 1;51(5):611-9. doi: 10.1086/655761. Erratum in: Clin Infect Dis. 2010 Nov 1;51(9):1114.

title: Is It Safe to Discontinue PrimaryPneumocystis jiroveciPneumonia Prophylaxis in Patients with Virologically Suppressed HIV Infection and a CD4 Cell Count <200 Cells/μL?

ReferenceCitation: Mocroft A, Phillips AN, Ledergerber B, Smith C, Bogner JR, Lacombe K, Wiercinska-Drapalo A, Reiss P, Kirk O, Lundgren JD; EuroSIDA Study Group. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. Antivir Ther. 2010;15(4):563-70. doi: 10.3851/IMP1559.

title: Estimated average annual rate of change of CD4+ T-cell counts in patients on combination antiretroviral therapy

ReferenceCitation: Trullas JC, Mocroft A, Cofan F, Tourret J, Moreno A, Bagnis CI, Fux CA, Katlama C, Reiss P, Lundgren J, Gatell JM, Kirk O, Miró JM; EuroSIDA Investigators. Dialysis and renal transplantation in HIV-infected patients: a European survey. J Acquir Immune Defic Syndr. 2010 Dec 15;55(5):582-9. doi: 10.1097/QAI.0b013e3181efbe59.

title: Dialysis and Renal Transplantation in HIV-Infected Patients: a European Survey

ReferenceCitation: Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk O, Phillips A, Sabin CA, Lundgren JD, Law MG; DAD study group. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501. doi: 10.1097/HJR.0b013e328336a150.

name: Copenhagen HIV Programme (CHIP), University of Copenhagen/Faculty of Health Science, Copenhagen, Denmark

name: Aquitaine, INSERM, ISPED, Université Victor Segalen Bordeaux, Bordeaux

name: ATHENA, HIV Monitoring Foundation, Academic Medical Center, Amsterdam, The Netherlands

name: SHCS, Division of Infectious Diseases and Hospital Epidemiolog, Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland

name: ICONA, Hospital San Paolo, University of Milan, Italy

name: Saint-Pierre Cohort, CHU Saint-Pierre Hospital, Brussels, Belgium

name: CPCRA, Columbia University/Harlem Hospital, New York, USA

name: Nice Cohort, CHU Nice Hopital de l'Archet, Nice, France

name: Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College, London, UK

name: AHOD, National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia

journal_name: European Journal of Cardiovascular Prevention & Rehabilitation

title: Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study

ReferenceCitation: Worm SW, Friis-Møller N, Bruyand M, D'Arminio Monforte A, Rickenbach M, Reiss P, El-Sadr W, Phillips A, Lundgren J, Sabin C; D:A:D study group. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. AIDS. 2010 Jan 28;24(3):427-35. doi: 10.1097/QAD.0b013e328334344e.

title: High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

ReferenceCitation: Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-Møller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010 Feb 1;201(3):318-30. doi: 10.1086/649897.

title: Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) Study

ReferenceCitation: Data Collection on Adverse Events of Anti-HIV drugs (D:A:D) Study Group, Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, Monforte Ad, Kirk O, Friis-Moller N, Phillips A, Reiss P, El Sadr W, Pradier C, Worm SW. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS. 2010 Jun 19;24(10):1537-48. doi: 10.1097/QAD.0b013e32833a0918. Erratum in: AIDS. 2011 Mar 27;25(6):883. multiple author names added.

title: Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study

ReferenceCitation: Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group, Weber R, Sabin C, Reiss P, de Wit S, Worm SW, Law M, Dabis F, D'Arminio Monforte A, Fontas E, El-Sadr W, Kirk O, Rickenbach M, Phillips A, Ledergerber B, Lundgren J. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Antivir Ther. 2010;15(8):1077-86. doi: 10.3851/IMP1681.

name: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group

title: HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study

ReferenceCitation: Peters L, Mocroft A, Soriano V, Rockstroh JK, Losso M, Valerio L, Aldins P, Reiss P, Ledergerber B, Lundgren JD; EuroSIDA Study Group. Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):457-63.

ReferenceCitation: Cozzi-Lepri A, Phillips AN, Martinez-Picado J, Monforte Ad, Katlama C, Eg Hansen AB, Horban A, Bruun J, Clotet B, Lundgren JD; EuroSIDA Study Group. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. J Infect Dis. 2009 Sep 1;200(5):687-97. doi: 10.1086/604731.

title: Rate of Accumulation of Thymidine Analogue Mutations in Patients Continuing to Receive Virologically Failing Regimens Containing Zidovudine or Stavudine: Implications for Antiretroviral Therapy Programs in Resource‐Limited Settings

ReferenceCitation: Kesselring AM, Wit FW, Sabin CA, Lundgren JD, Gill MJ, Gatell JM, Rauch A, Montaner JS, de Wolf F, Reiss P, Mocroft A; Nevirapine Toxicity Multicohort Collaboration. Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS. 2009 Aug 24;23(13):1689-99. doi: 10.1097/QAD.0b013e32832d3b54.

title: Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy

ReferenceCitation: Worm SW, De Wit S, Weber R, Sabin CA, Reiss P, El-Sadr W, Monforte AD, Kirk O, Fontas E, Dabis F, Law MG, Lundgren JD, Friis-Møller N. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation. 2009 Feb 17;119(6):805-11. doi: 10.1161/CIRCULATIONAHA.108.790857. Epub 2009 Feb 2.

name: From Copenhagen HIV Programme (CHIP), University of Copenhagen (S.W.W., O.K., J.D.L., N.F.-M.), Copenhagen, Denmark; CHU Saint-Pierre Hospital, Department of Infectious Diseases (S.D.W.), Bruxelles, Belgium; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich (R.W.), Zurich, Switzerland; Research Department of Infection and Population Health (C.A.S.), UCL, London, United Kingdom; HIV Monitoring Foundation (P.R.), Academic Medical Center, Amsterdam, Netherlands;...

title: Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus

ReferenceCitation: Worm SW, Sabin CA, Reiss P, El-Sadr W, Monforte Ad, Pradier C, Thiebaut R, Law M, Rickenbach M, De Wit S, Lundgren JD, Friis-Møller N. Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study. Diabetes Care. 2009 Mar;32(3):474-80. doi: 10.2337/dc08-1394. Epub 2008 Dec 3.

repository_institution: The Pennsylvania State University - CiteSeer X

repositories:
CiteSeerX
PubMed Central
dipot.ulb.ac.be

repositories_institution: The Pennsylvania State University - CiteSeer X

title: Presence of the Metabolic Syndrome Is Not a Better Predictor of Cardiovascular Disease Than the Sum of Its Components in HIV-Infected Individuals: Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study

ReferenceCitation: When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miró JM, Justice AC, Ledergerber B, Fätkenheuer G, Hogg RS, Monforte AD, Saag M, Smith C, Staszewski S, Egger M, Cole SR. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009 Apr 18;373(9672):1352-63. doi: 10.1016/S0140-6736(09)60612-7. Epub 2009 Apr 8. Review.

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Inserm

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - memSIC

repositories_institution: Le Centre pour la Communication Scientifique Directe - HAL - Inserm

repositories_institution: Le Centre pour la Communication Scientifique Directe - HAL - memSIC

title: Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

ReferenceCitation: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group, Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro Murillo AM, Mocroft A, Bonnet F, Clifford G, Touloumi G, Miro JM, Chene G, Lundgren J, Egger M. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. AIDS. 2009 Sep 24;23(15):2029-37. doi: 10.1097/QAD.0b013e32832e531c.

title: Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy

ReferenceCitation: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Karafoulidou A, Miro JM, Lundgren J, Chene G, Egger M. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther. 2009;14(8):1065-74. doi: 10.3851/IMP1462.

name: The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Aix-Marseille Université

repositories_institution: Le Centre pour la Communication Scientifique Directe - HAL - Aix-Marseille Université

title: Incidence and risk factors of HIV-related non-Hodgkin’s lymphoma in the era of combination antiretroviral therapy: a European multicohort study

ReferenceCitation: Podlekareva DN, Mocroft A, Post FA, Riekstina V, Miro JM, Furrer H, Bruyand M, Panteleev AM, Rakhmanova AG, Girardi E, Losso MH, Toibaro JJ, Caylá J, Miller RF, Obel N, Skrahina A, Chentsova N, Lundgren JD, Kirk O; HIV/TB Study Writing Group. Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. AIDS. 2009 Nov 27;23(18):2485-95. doi: 10.1097/QAD.0b013e3283326879.

title: Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina

ReferenceCitation: antiretroviral therapy cohort collaboration (ART-CC), Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chêne G, Furrer H, Sterling T, Monforte AD, Force L, Gill J, Harris R, Hogg RS, Rockstroh J, Saag M, Khaykin P, de Wolf F, Sterne JA, Costagliola D. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS. 2009 Oct 23;23(16):2199-208. doi: 10.1097/QAD.0b013e3283305a00.

title: Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements

ReferenceCitation: Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, Justice A, Mocroft A, Reiss P, Lampe F, Chêne G, Costagliola D, Elzi L, Mugavero MJ, Monforte AD, Sabin C, Podzamczer D, Fätkenheuer G, Staszewski S, Gill J, Sterne JA; Antiretroviral Therapy Cohort Collaboration. Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):357-63. doi: 10.1097/QAI.0b013e3181b62933.

title: Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression

ReferenceCitation: Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis. 2009 Apr 15;48(8):1138-51. doi: 10.1086/597468.

name: Antiretroviral Therapy Cohort Collaboration (ART‐CC)

title: Variable Impact on Mortality of AIDS‐Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS‐Defining Conditions Are Created Equal

ReferenceCitation: Mocroft A, Horban A, Clotet B, d'Arminio Monforte A, Bogner JR, Aldins P, Staub T, Antunes F, Katlama C, Lundgren JD; EuroSIDA Study Group. Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999. HIV Med. 2008 Jan;9(1):41-6. doi: 10.1111/j.1468-1293.2008.00519.x.

title: Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999

ReferenceCitation: Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, Vetter N, Dabis F, Gatell J, Lundgren JD; EuroSIDA study group. Loss to follow-up in an international, multicentre observational study. HIV Med. 2008 May;9(5):261-9. doi: 10.1111/j.1468-1293.2008.00557.x.

title: Loss to follow-up in an international, multicentre observational study

ReferenceCitation: D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008 Apr 26;371(9622):1417-26. doi: 10.1016/S0140-6736(08)60423-7. Epub 2008 Apr 2. Erratum in: Lancet. 2008 Jul 26;372(9635):292.

title: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

ReferenceCitation: Deforche K, Cozzi-Lepri A, Theys K, Clotet B, Camacho RJ, Kjaer J, Van Laethem K, Phillips A, Moreau Y, Lundgren JD, Vandamme AM; EuroSIDA Study Group. Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response. Antivir Ther. 2008;13(3):399-407.

ReferenceCitation: Podlekareva D, Mocroft A, Kirk O, Reiss P, Aldins P, Katlama C, Kovari H, Stellbrink HJ, D'Arminio Monforte A, Lundgren JD; Eurosida Study Group. Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART. Scand J Infect Dis. 2008;40(11-12):908-13. doi: 10.1080/00365540802227094.

journal_name: Scandinavian Journal of Infectious Diseases

title: Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/µl in the era of cART

ReferenceCitation: Cozzi-Lepri A, Phillips AN, Clotet B, Mocroft A, Ruiz L, Kirk O, Lazzarin A, Wiercinska-Drapalo A, Karlsson A, Lundgren JD; EuroSIDA Study Group. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. AIDS. 2008 Oct 18;22(16):2187-98. doi: 10.1097/QAD.0b013e328310e04f.

title: Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study

ReferenceCitation: Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A, van Lunzen J, Clumeck N, Kirk O, Gazzard B, Lundgren JD; EuroSIDA Study Group. Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? AIDS. 2008 Nov 12;22(17):2381-90. doi: 10.1097/QAD.0b013e328317a6eb.

title: Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?

ReferenceCitation: Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, Peters L, Karlsson A, Katlama C, Toro C, Kupfer B, Vogel M, Lundgren J; EuroSIDA Study Group. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis. 2008 Nov 1;198(9):1337-44. doi: 10.1086/592171.

title: Spontaneous Viral Clearance, Viral Load, and Genotype Distribution of Hepatitis C Virus (HCV) in HIV‐Infected Patients with Anti‐HCV Antibodies in Europe

ReferenceCitation: Antiretroviral Therapy Cohort Collaboration (ART-CC), Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Günthard HF, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Lampe F, Miró JM, Staszewski S, Sterne JA. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS. 2008 Nov 30;22(18):2481-92. doi: 10.1097/QAD.0b013e328318f130.

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Inria

repositories_institution: Le Centre pour la Communication Scientifique Directe - HAL - Inria

title: Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

ReferenceCitation: Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008 Jul 26;372(9635):293-9. doi: 10.1016/S0140-6736(08)61113-7.

title: Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

ReferenceCitation: Monforte Ad, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, Kirk O, Law M, De Wit S, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS. 2008 Oct 18;22(16):2143-53. doi: 10.1097/QAD.0b013e3283112b77.

title: HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

ReferenceCitation: Data Collection on Adverse Events of Anti-HIV Drugs Study Group, Sabin CA, d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis. 2008 Apr 1;46(7):1101-10. doi: 10.1086/528862.

name: Data Collection on Adverse Events of Anti‐HIV Drugs Study Group

title: Changes Over Time in Risk Factors for Cardiovascular Disease and Use of Lipid‐Lowering Drugs in HIV‐Infected Individuals and Impact on Myocardial Infarction

ReferenceCitation: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Sabin CA, Smith CJ, d'Arminio Monforte A, Battegay M, Gabiano C, Galli L, Geelen S, Gibb D, Guiguet M, Judd A, Leport C, Dabis F, Pantazis N, Porter K, Raffi F, Thorne C, Torti C, Walker S, Warszawski J, Wintergerst U, Chene G, Lundgren J. Response to combination antiretroviral therapy: variation by age. AIDS. 2008 Jul 31;22(12):1463-73. doi: 10.1097/QAD.0b013e3282f88d02.

title: Response to combination antiretroviral therapy: variation by age

ReferenceCitation: Harris RJ, Sterne JA, Abgrall S, Dabis F, Reiss P, Saag M, Phillips AN, Chêne G, Gill JM, Justice AC, Rockstroh J, Sabin CA, Mocroft A, Bucher HC, Hogg RS, Monforte AD, May M, Egger M; Antiretroviral Therapy Cohort Collaboration. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Antivir Ther. 2008;13(8):959-67.

ReferenceCitation: De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, El-Sadr W, Monforte Ad, Fontas E, Law MG, Friis-Møller N, Phillips A; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care. 2008 Jun;31(6):1224-9. doi: 10.2337/dc07-2013. Epub 2008 Feb 11.

title: Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study

ReferenceCitation: Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 2008 Sep 12;22(14):F17-24. doi: 10.1097/QAD.0b013e32830fe35e.

title: Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

ReferenceCitation: Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, Mens H, Clumeck N, Viksna L, Antunes F, Machala L, Lundgren JD; EuroSIDA Study Group. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS. 2007 Mar 30;21(6):721-32.

ReferenceCitation: Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips AN, Lundgren JD; EuroSIDA study group. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med. 2007 Mar;8(2):96-104.

ReferenceCitation: DAD Study Group, Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte Ad, El-Sadr W, Thiébaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007 Apr 26;356(17):1723-35.

ReferenceCitation: Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, Zilmer K, Beniowski M, Viard JP, Staszewski S, Lundgren JD. Chronic renal failure among HIV-1-infected patients. AIDS. 2007 May 31;21(9):1119-27.

ReferenceCitation: Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, Losso M, Lazzarin A, Fatkenheuer G, Lundgren JD; EuroSIDA study group. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet. 2007 Aug 4;370(9585):407-13.

ReferenceCitation: Kowalska JD, Mocroft A, Blaxhult A, Colebunders R, van Lunzen J, Podlekareva D, Hansen AB, Machala L, Yust I, Benfield T; EuroSIDA Study Group. Current hemoglobin levels are more predictive of disease progression than hemoglobin measured at baseline in patients receiving antiretroviral treatment for HIV type 1 infection. AIDS Res Hum Retroviruses. 2007 Oct;23(10):1183-8.

ReferenceCitation: Ceccherini-Silberstein F, Cozzi-Lepri A, Ruiz L, Mocroft A, Phillips AN, Olsen CH, Gatell JM, Gunthard HF, Reiss P, Perno CF, Clotet B, Lundgren JD; EuroSIDA Study Group. Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients. J Infect Dis. 2007 Oct 15;196(8):1180-90. Epub 2007 Sep 19.

ReferenceCitation: Fox ZV, Geretti AM, Kjaer J, Dragsted UB, Phillips AN, Gerstoft J, Staszewski S, Clotet B, von Wyl V, Lundgren JD. The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. AIDS. 2007 Oct 1;21(15):2033-42.

ReferenceCitation: Mocroft A, Staszewski S, Weber R, Gatell J, Rockstroh J, Gasiorowski J, Panos G, Monforte Ad, Rakhmanova A, Phillips AN, Lundgren JD; EuroSIDA study group. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts. Antivir Ther. 2007;12(3):325-33. Erratum in: Antivir Ther. 2007;12(4):577.

ReferenceCitation: Antiretroviral Therapy in Low-Income Countries Collaboration of the International epidemiological Databases to Evaluate AIDS (IeDEA); ART Cohort Collaboration, Brinkhof MW, Egger M, Boulle A, May M, Hosseinipour M, Sprinz E, Braitstein P, Dabis F, Reiss P, Bangsberg DR, Rickenbach M, Miro JM, Myer L, Mocroft A, Nash D, Keiser O, Pascoe M, van der Borght S, Schechter M. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis. 2007 Dec 1;45(11):1518-21. Epub 2007 Oct 22.

ReferenceCitation: Antiretroviral Therapy Cohort Collaboration. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients. J Acquir Immune Defic Syndr. 2007 Dec 15;46(5):607-15.

ReferenceCitation: May M, Sterne JA, Shipley M, Brunner E, d'Agostino R, Whincup P, Ben-Shlomo Y, Carr A, Ledergerber B, Lundgren JD, Phillips AN, Massaro J, Egger M. A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. Int J Epidemiol. 2007 Dec;36(6):1309-18. Epub 2007 Jul 25.

ReferenceCitation: Sterne JA, May M, Bucher HC, Ledergerber B, Furrer H, Cavassini M, Bernasconi E, Hirschel B, Egger M; Swiss HIV Cohort. HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy. J Intern Med. 2007 Mar;261(3):255-67.

ReferenceCitation: Llibre JM, Cozzi-Lepri A, La Rosa JA, Pedersen C, Ristola M, Losso M, Mocroft A, Mitsura VM, Ormaasen V, Maltez F, Beniowski M, Paredes R; Eurosida in Eurocoord. Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19810. doi: 10.7448/IAS.17.4.19810. eCollection 2014.

title: Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression

ReferenceCitation: Schultze A, Paredes R, Sabin C, Phillips AN, Pillay D, Kirk O, Lundgren JD, Pozniak A, Nelson M, Cozzi-Lepri A; Eurosida in Eurocoord. Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19737. doi: 10.7448/IAS.17.4.19737. eCollection 2014.

title: Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure

ReferenceCitation: Fontdevila MC, Cozzi-Lepri A, Phillips A, Julian MN, Bickel M, Sedlacek D, Kronborg G, Lazzarin A, Zilmer K, Clotet B, Lundgren JD, Paredes R. Plasma HIV-1 tropism and risk of short-term clinical progression to AIDS or death. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19685. doi: 10.7448/IAS.17.4.19685. eCollection 2014.

evidence: oa repository (via OAI-PMH title and last author match)

title: Plasma HIV-1 tropism and risk of short-term clinical progression to AIDS or death

ReferenceCitation: Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, Gatell J, Rakhmanova A, Johnson M, Kirk O, Lundgren J; EuroSIDA Study Group. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr. 2010 Oct;55(2):262-70. doi: 10.1097/QAI.0b013e3181e9be6b.

title: Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe

ReferenceCitation: Young J, Bucher HC, Guenthard HF, Rickenbach M, Fux CA, Hirschel B, Cavassini M, Vernazza P, Bernasconi E, Battegay M; Swiss HIV Cohort Study. Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. Antivir Ther. 2009;14(6):771-9. doi: 10.3851/IMP1291.

title: Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV

ReferenceCitation: Smith CJ, Mocroft A, Lundgren JD; EuroSIDA Study Group. Incidence of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy. AIDS. 2008 May 11;22(8):997-8. doi: 10.1097/QAD.0b013e3282ffb0fd.

title: Incidence of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy

ReferenceCitation: Bannister WP, Ruiz L, Loveday C, Vella S, Zilmer K, Kjaer J, Knysz B, Phillips AN, Mocroft A; EuroSIDA Study Group. HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antivir Ther. 2006;11(6):707-15.

ReferenceCitation: Mocroft, Horban, Clumeck, Stellbrink, Monforte dA, Zilmer, Kirk, Gatell, Phillips, Lundgren; EuroSIDA Study Group. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000. HIV Clin Trials. 2006 Nov-Dec;7(6):271-84.

ReferenceCitation: Mocroft A, Rockstroh J, Soriano V, Kirk O, Viard JP, Caplinskas S, Gasiorowski J, Chiesi A, Phillips AN, Lundgren JD; EuroSIDA Study Group. Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. Scand J Infect Dis. 2006;38(11-12):1092-7.

ReferenceCitation: Mocroft A, Neaton J, Bebchuk J, Staszewski S, Antunes F, Knysz B, Law M, Phillips AN, Lundgren JD; EuroSIDA Study Group; ESPRIT Study Group. The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. Clin Trials. 2006;3(2):119-32.

ReferenceCitation: Bannister WP, Kirk O, Gatell JM, Knysz B, Viard JP, Mens H, Monforte AD, Phillips AN, Mocroft A, Lundgren JD; EuroSIDA Study Group. Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe. J Acquir Immune Defic Syndr. 2006 Jun;42(2):229-37.

ReferenceCitation: Rockstroh JK. Influence of viral hepatitis on HIV infection. J Hepatol. 2006;44(1 Suppl):S25-7. Epub 2005 Nov 21. Review.

ReferenceCitation: Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E, Sterne JA, May M, Egger M; Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration; ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006 Mar 11;367(9513):817-24. Erratum in: Lancet. 2006 Jun 10;367(9526):1902.

ReferenceCitation: Law MG, Friis-Møller N, El-Sadr WM, Weber R, Reiss P, D'Arminio Monforte A, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Kirk O, Sabin CA, Phillips AN, Lundgren JD; D:A:D Study Group. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med. 2006 May;7(4):218-30.

ReferenceCitation: Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD, Knysz B, Antunes F, Reiss P, Lundgren JD. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia. AIDS. 2006 May 12;20(8):1141-50.

ReferenceCitation: Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte Ad, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med. 2006 Aug 14-28;166(15):1632-41.

ReferenceCitation: Puoti M, Cozzi-Lepri A, Paraninfo G, Arici C, Moller NF, Lundgren JD, Ledergerber B, Rickenbach M, Suarez-Lozano I, Garrido M, Dabis F, Winnock M, Milazzo L, Gervais A, Raffi F, Gill J, Rockstroh J, Ourishi N, Mussini C, Castagna A, De Luca A, Monforte Ad; HBV-HIV International Intercohort Study Group. Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. Antivir Ther. 2006;11(5):567-74. Erratum in: Antivir Ther. 2006;11(6):831. Paraninfo, Giuseppe [added].

ReferenceCitation: May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F, Fätkenheuer G, Staszewski S, d'Arminio Monforte A, Egger M; Antiretroviral Therapy (ART) Cohort Collaboration. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet. 2006 Aug 5;368(9534):451-8. Review.

ReferenceCitation: Antiretroviral Therapy Cohort Collaboration. Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies. J Infect Dis. 2006 Sep 1;194(5):612-22. Epub 2006 Jul 31.

ReferenceCitation: Cozzi-Lepri A, Ruiz L, Loveday C, Phillips AN, Clotet B, Reiss P, Ledergerber B, Holkmann C, Staszewski S, Lundgren JD; EuroSIDA Study Group. Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther. 2005;10(7):791-802.

ReferenceCitation: Mocroft A, Rockstroh J, Soriano V, Ledergerber B, Kirk O, Vinogradova E, Reiss P, Katlama C, Phillips AN, Lundgren JD; EuroSIDA Study Group. Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? Antivir Ther. 2005;10(7):779-90.

ReferenceCitation: Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, de Wit S, Gatell J, Clotet B, Phillips AN, Lundgren JD; EuroSIDA Study Group. Is there evidence for an increase in the death rate from liver-related disease in patients with HIV? AIDS. 2005 Dec 2;19(18):2117-25.

ReferenceCitation: Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C, Boron-Kaczmarska A, Viksna L, Kirk O, Lundgren JD; EuroSIDA Study Group. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses. 2005 Sep;21(9):743-52.

ReferenceCitation: Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J; EuroSIDA Study Group. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005 Sep 15;192(6):992-1002. Epub 2005 Aug 11.

ReferenceCitation: Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C, Boron-Kaczmarska A, Viksna L, Kirk O, Lundgren JD; EuroSIDA Study Group. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses. 2005 Jun;21(6):527-36.

ReferenceCitation: Mocroft A, Oancea C, van Lunzen J, Vanhems P, Banhegyi D, Chiesi A, Vinogradova E, Maayan S, Phillips AN, Lundgren J; EuroSIDA study group. Decline in esophageal candidiasis and use of antimycotics in European patients with HIV. Am J Gastroenterol. 2005 Jul;100(7):1446-54.

ReferenceCitation: Olsen CH, Gatell J, Ledergerber B, Katlama C, Friis-Møller N, Weber J, Horban A, Staszewski S, Lundgren JD, Phillips AN; EuroSIDA Study Group. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. AIDS. 2005 Feb 18;19(3):319-30.

ReferenceCitation: Mocroft A, Gatell J, Reiss P, Ledergerber B, Kirk O, Vella S, Blaxhult A, Phillips AN, Lundgren J; EuroSIDA study group. Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy. AIDS. 2004 Nov 19;18(17):2333-7.

ReferenceCitation: Phillips AN, Ledergerber B, Horban A, Reiss P, Chiesi A, Kirk O, Mulchany F, Fisher M, Machala L, Lundgren JD; EuroSIDA Study Group. Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. AIDS. 2004 Sep 3;18(13):1795-804.

ReferenceCitation: Lundgren JD, Mocroft A. Anemia and survival in human immunodeficiency virus. Clin Infect Dis. 2003;37 Suppl 4:S297-303.

ReferenceCitation: Mocroft A, Ruiz L, Reiss P, Ledergerber B, Katlama C, Lazzarin A, Goebel FD, Phillips AN, Clotet B, Lundgren JD; EuroSIDA study group. Virological rebound after suppression on highly active antiretroviral therapy. AIDS. 2003 Aug 15;17(12):1741-51.

ReferenceCitation: Cozzi-Lepri A, Phillips AN, Miller V, Katlama C, Ledergerber B, Vella S, Weber J, Bruun JN, Kirk O, Clotet B, Lundgrens JD. Changes in viral load in people with virological failure who remain on the same HAART regimen. Antivir Ther. 2003 Apr;8(2):127-36.

ReferenceCitation: Moore AL, Kirk O, Johnson AM, Katlama C, Blaxhult A, Dietrich M, Colebunders R, Chiesi A, Lungren JD, Phillips AN; EuroSIDA group. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr. 2003 Apr 1;32(4):452-61.

ReferenceCitation: Blaxhult A, Fox Z, Colebunders R, Francioli P, Ben-Ishai Z, Fätkenheuer G, Parkin JM, Vanhems P, Phillips AN, Kirk O; EuroSIDA Study Group. Regional and temporal changes in AIDS in Europe before HAART. Epidemiol Infect. 2002 Dec;129(3):565-76.

ReferenceCitation: Kirk O, Pedersen C, Law M, Gulick RM, Moyle G, Montaner J, Eron JJ Jr, Phillips AN, Lundgren JD. Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy. Antivir Ther. 2002 Dec;7(4):271-81.

ReferenceCitation: Kirk O, Reiss P, Uberti-Foppa C, Bickel M, Gerstoft J, Pradier C, Wit FW, Ledergerber B, Lundgren JD, Furrer H; European HIV Cohorts. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med. 2002 Aug 20;137(4):239-50.

ReferenceCitation: Phillips AN, Pradier C, Lazzarin A, Clotet B, Goebel FD, Hermans P, Antunes F, Ledergerber B, Kirk O, Lundgren JD; EuroSIDA Study Group. Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS. 2001 Dec 7;15(18):2385-95.

ReferenceCitation: Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, Vernazza P, Lundgren JD, Ledergerber B; Swiss HIV Cohort Study; Frakfurt HIV Clinic Cohort; EuroSIDA Study Group. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA. 2001 Nov 28;286(20):2560-7.

ReferenceCitation: Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, Miller V, Gatell JM, Katlama C, Lazzarin A, Skinhøj P, Barton SE; EuroSIDA Study Group. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood. 2001 Dec 1;98(12):3406-12.

ReferenceCitation: Kirk O, Mocroft A, Pradier C, Bruun JN, Hemmer R, Clotet B, Miller V, Viard JP, Phillips AN, Lundgren JD; EuroSIDA Study Group. Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir. AIDS. 2001 May 25;15(8):999-1008.

ReferenceCitation: Norton M. Stopping PCP prophylaxis after suppressing HIV. GMHC Treat Issues. 1999 Apr;13(4):4-5.

ReferenceCitation: Thiébaut R, El-Sadr WM, Friis-Møller N, Rickenbach M, Reiss P, Monforte AD, Morfeldt L, Fontas E, Kirk O, De Wit S, Calvo G, Law MG, Dabis F, Sabin CA, Lundgren JD; Data Collection of Adverse events of anti-HIV Drugs Study Group. Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther. 2005;10(7):811-23. Erratum in: Antivir Ther. 2005;10(8):969.

ReferenceCitation: Girardi E, Sabin CA, d'Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, Dabis F, Reiss P, Kirk O, Bernasconi E, Grabar S, Justice A, Staszewski S, Fätkenheuer G, Sterne JA; Antiretroviral Therapy Cohort Collaboration. Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis. 2005 Dec 15;41(12):1772-82. Epub 2005 Nov 11.

ReferenceCitation: Sabine C; Antiretroviral Therapy (ART) Cohort Collaboration. AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? AIDS. 2005 Nov 18;19(17):1995-2000.

ReferenceCitation: May M, Porter K, Sterne JA, Royston P, Egger M. Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. J Clin Epidemiol. 2005 Oct;58(10):1033-41.

ReferenceCitation: d'Arminio Monforte A, Sabin CA, Phillips A, Sterne J, May M, Justice A, Dabis F, Grabar S, Ledergerber B, Gill J, Reiss P, Egger M; Antiretroviral Therapy Cohort Collaboration. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med. 2005 Feb 28;165(4):416-23. Erratum in: Arch Intern Med. 2005 May 23;165(10):1200.

ReferenceCitation: Fontas E, van Leth F, Sabin CA, Friis-Møller N, Rickenbach M, d'Arminio Monforte A, Kirk O, Dupon M, Morfeldt L, Mateu S, Petoumenos K, El-Sadr W, de Wit S, Lundgren JD, Pradier C, Reiss P; D:A:D Study Group. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004 Mar 15;189(6):1056-74. Epub 2004 Mar 2.

ReferenceCitation: Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe F, Gill MJ, Castelli F, Phillips AN; PLATO Collaboration. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004 Jul 3-9;364(9428):51-62.

ReferenceCitation: d'Arminio A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, El-Sadr W, De Wit S, Mateu S, Petoumenos K, Dabis F, Pradier C, Morfeldt L, Lundgren JD, Friis-Møller N; Writing Committee of the D:A:D: Study Group. Cardio- and cerebrovascular events in HIV-infected persons. AIDS. 2004 Sep 3;18(13):1811-7.

ReferenceCitation: Collaboration of HIV Cohorts. Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound. J Infect Dis. 2004 Aug 15;190(4):675-87. Epub 2004 Jul 19.

ReferenceCitation: Law M, Friis-Møller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Calvo G, El-Sadr W, De Wit S, Sabin CA, Lundgren JD; DAD Study Group. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med. 2003 Jan;4(1):1-10.

ReferenceCitation: May M, Royston P, Egger M, Justice AC, Sterne JA; ART Cohort Collaboration. Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. Stat Med. 2004 Aug 15;23(15):2375-98.

ReferenceCitation: Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD; DAD study group. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS. 2003 May 23;17(8):1179-93.

ReferenceCitation: Chêne G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, D'Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME; Antiretroviral Therapy Cohort Collaboration. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003 Aug 30;362(9385):679-86.

ReferenceCitation: Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003 Nov 20;349(21):1993-2003. Erratum in: N Engl J Med. 2004 Feb 26;350(9):955.

ReferenceCitation: Miller V, Phillips AN, Clotet B, Mocroft A, Ledergerber B, Kirk O, Ormaasen V, Gargalianos-Kakolyris P, Vella S, Lundgren JD. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis. 2002 Jul 15;186(2):189-97. Epub 2002 Jul 3.

ReferenceCitation: Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA; ART Cohort Collaboration. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002 Jul 13;360(9327):119-29. Erratum in: Lancet 2002 Oct 12;360(9340):1178.

ReferenceCitation: Ledergerber B, Mocroft A, Reiss P, Furrer H, Kirk O, Bickel M, Uberti-Foppa C, Pradier C, D'Arminio Monforte A, Schneider MM, Lundgren JD; Eight European Study Groups. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med. 2001 Jan 18;344(3):168-74.

location_country:
Luxembourg
Finland
Greece
Romania
Belgium
Russian Federation
Denmark
Iceland
Ukraine
Spain
Croatia
France
Lithuania
Poland
Slovakia
Norway
Argentina
Slovenia
Sweden
Switzerland
Netherlands
Hungary
Ireland
Portugal
Germany
United Kingdom
Italy
Austria
Bosnia and Herzegovina
Serbia
Czechia
Israel
Georgia
Belarus
Estonia
Latvia

location_facility: GOCGEIOZ - Gomel Regional Centre for Hygiene

location_facility: The General Hospital of Athens "G. Gennimatas"

location_facility: Centre hospitalier Universitaire Vaudois

location_facility: Ospedale Cotugno, III Divisione Malattie Infettive

location_facility: Lviv Regional HIV/AIDS Prevention and Control CTR

location_facility: Hospital Clínic, University of Barcelona

location_facility: Wojewodzki Szpital Specjalistyczny im. WI. Bieganskiego

location_facility: Consorcio Hospital General Universitario Valencia

location_facility: Vilnius University Hospital Santariskiu Klinikos

location_facility: Bernhard Nocht Institut für Tropenmedizin

location_facility: Novgorod Centre for AIDS prevention and control

location_facility: Szpital Specjalistyczny, Osrodek Diagnostyki i Terapii AIDS

location_facility: Klinicki centar Univerziteta Sarajevo (KCUS)

location_facility: Nizhny Novgorod Scientific and Research Institute

location_facility: Kaplan Medical Center, AIDS Center Neve Or

location_facility: Centre for HIV/AIDS & and infectious diseases

location_facility: National Institute for Infectious Diseases

location_facility: University Hospital of Infectious Diseases

location_facility: The Institute for Infectious and Tropical Diseases

location_facility: Infectious Diseases and Tuberculosis Hospital, Vilnius University Hospital branch

location_facility: Academisch Ziekenhuis bij de Universiteit van Amsterdam

location_facility: Georgian AIDS and Clinical Immunology Research Center

location_facility: Hospital Universitari Germans Trias i Pujol

location_facility: Hospital Carlos III, Departamento de Enfermedades Infecciosas

location_facility: University College London, Mortimer Market Centre

location_facility: Ospedale Riuniti, Divisione Malattie Infettive